NO310075B1 - AZA spiroforbindelser som virker på det cholinergiske system med muscarinisk agonistaktivitet, anvendelse av samme for fremstilling av medikament, farmasöytisk sammensetning omfattende samme samt kjemisk forbindelse til bruk som medikament - Google Patents

AZA spiroforbindelser som virker på det cholinergiske system med muscarinisk agonistaktivitet, anvendelse av samme for fremstilling av medikament, farmasöytisk sammensetning omfattende samme samt kjemisk forbindelse til bruk som medikament Download PDF

Info

Publication number: NO310075B1
Authority: NO; Norway
Prior art keywords: spiro; methyl; methylpiperidine; ethyl; methylpiperidin
Prior art date: 1993-07-20

Application number

NO960225A

Other languages

English (en)

Norwegian (no)

Other versions

NO960225D0 (no

NO960225L (no

Inventor

Abraham Fisher

Yishai Karton

Daniele Marciano

Dov Barak

Haim Meshulam

Original Assignee

Israel State

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-07-20

Filing date

1996-01-18

Publication date

2001-05-14

1996-01-18 Application filed by Israel State filed Critical Israel State

1996-01-18 Publication of NO960225D0 publication Critical patent/NO960225D0/no

1996-03-12 Publication of NO960225L publication Critical patent/NO960225L/no

2001-05-14 Publication of NO310075B1 publication Critical patent/NO310075B1/no

Links

150000001875 compounds Chemical class 0.000 title claims description 192
239000003814 drug Substances 0.000 title claims description 18
230000001713 cholinergic effect Effects 0.000 title claims description 15
239000008194 pharmaceutical composition Substances 0.000 title claims description 10
230000000694 effects Effects 0.000 title description 76
239000000472 muscarinic agonist Substances 0.000 title description 15
238000004519 manufacturing process Methods 0.000 title description 3
150000008627 azaspiro compounds Chemical class 0.000 title 1
208000024827 Alzheimer disease Diseases 0.000 claims description 44
238000011282 treatment Methods 0.000 claims description 44
-1 3-ethyl-2 Chemical compound 0.000 claims description 32
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 27
150000003413 spiro compounds Chemical class 0.000 claims description 24
229910052757 nitrogen Inorganic materials 0.000 claims description 21
150000003839 salts Chemical class 0.000 claims description 21
208000024891 symptom Diseases 0.000 claims description 21
238000002360 preparation method Methods 0.000 claims description 19
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 18
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 18
201000010099 disease Diseases 0.000 claims description 14
208000035475 disorder Diseases 0.000 claims description 13
229940091173 hydantoin Drugs 0.000 claims description 12
208000018737 Parkinson disease Diseases 0.000 claims description 11
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 8
MZQQHYDUINOMDG-UHFFFAOYSA-N 3-methylimidazolidine-2,4-dione Chemical compound CN1C(=O)CNC1=O MZQQHYDUINOMDG-UHFFFAOYSA-N 0.000 claims description 8
125000004433 nitrogen atom Chemical group N* 0.000 claims description 8
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 7
206010003591 Ataxia Diseases 0.000 claims description 7
125000000217 alkyl group Chemical group 0.000 claims description 7
206010019196 Head injury Diseases 0.000 claims description 6
125000003118 aryl group Chemical group 0.000 claims description 6
125000004122 cyclic group Chemical group 0.000 claims description 6
229910052739 hydrogen Inorganic materials 0.000 claims description 6
OHOJRYNNXNLLOK-UHFFFAOYSA-N imidazolidine-2,4-dithione Chemical compound S=C1CNC(=S)N1 OHOJRYNNXNLLOK-UHFFFAOYSA-N 0.000 claims description 6
125000003003 spiro group Chemical group 0.000 claims description 6
241000124008 Mammalia Species 0.000 claims description 5
RHYBFKMFHLPQPH-UHFFFAOYSA-N N-methylhydantoin Natural products CN1CC(=O)NC1=O RHYBFKMFHLPQPH-UHFFFAOYSA-N 0.000 claims description 5
239000001257 hydrogen Substances 0.000 claims description 5
UMURLIQHQSKULR-UHFFFAOYSA-N 1,3-oxazolidine-2-thione Chemical compound S=C1NCCO1 UMURLIQHQSKULR-UHFFFAOYSA-N 0.000 claims description 4
PZRTWEJREZGWCF-UHFFFAOYSA-N 1-acetylimidazolidine-2,4-dione Chemical compound CC(=O)N1CC(=O)NC1=O PZRTWEJREZGWCF-UHFFFAOYSA-N 0.000 claims description 4
RCSBKGMLSAWCGQ-UHFFFAOYSA-N 1-ethyl-5-sulfanylideneimidazolidin-2-one Chemical compound CCN1C(=O)NCC1=S RCSBKGMLSAWCGQ-UHFFFAOYSA-N 0.000 claims description 4
JUIQOABNSLTJSW-UHFFFAOYSA-N 2-Methyl-4,5-dihydro-1,3-thiazole Chemical compound CC1=NCCS1 JUIQOABNSLTJSW-UHFFFAOYSA-N 0.000 claims description 4
SVSVCYZPFWDAPW-UHFFFAOYSA-N 2-methyl-1,3-oxazol-4-one Chemical compound CC1=NC(=O)CO1 SVSVCYZPFWDAPW-UHFFFAOYSA-N 0.000 claims description 4
VWSLLSXLURJCDF-UHFFFAOYSA-N 2-methyl-4,5-dihydro-1h-imidazole Chemical compound CC1=NCCN1 VWSLLSXLURJCDF-UHFFFAOYSA-N 0.000 claims description 4
UGWULZWUXSCWPX-UHFFFAOYSA-N 2-sulfanylideneimidazolidin-4-one Chemical compound O=C1CNC(=S)N1 UGWULZWUXSCWPX-UHFFFAOYSA-N 0.000 claims description 4
BELGHMWMXFCZTP-UHFFFAOYSA-N 3-ethyl-1,3-oxazolidin-2-one Chemical compound CCN1CCOC1=O BELGHMWMXFCZTP-UHFFFAOYSA-N 0.000 claims description 4
PVGKKACSLZHMQT-UHFFFAOYSA-N 3-ethylimidazolidine-2,4-dione Chemical compound CCN1C(=O)CNC1=O PVGKKACSLZHMQT-UHFFFAOYSA-N 0.000 claims description 4
CKJKXGCEEQEXJV-UHFFFAOYSA-N 3-prop-2-ynylimidazolidine-2,4-dione Chemical compound O=C1CNC(=O)N1CC#C CKJKXGCEEQEXJV-UHFFFAOYSA-N 0.000 claims description 4
ODWHOLJOSAERBD-UHFFFAOYSA-N 5-ethyl-1,3-thiazolidin-4-one Chemical compound CCC1SCNC1=O ODWHOLJOSAERBD-UHFFFAOYSA-N 0.000 claims description 4
RDGGWORUSWZUHI-UHFFFAOYSA-N 5-methyl-1,3-oxazolidin-4-one Chemical compound CC1OCNC1=O RDGGWORUSWZUHI-UHFFFAOYSA-N 0.000 claims description 4
GHAZCVNUKKZTLG-UHFFFAOYSA-N N-ethylsuccinimide Chemical compound CCN1C(=O)CCC1=O GHAZCVNUKKZTLG-UHFFFAOYSA-N 0.000 claims description 4
206010039966 Senile dementia Diseases 0.000 claims description 4
208000006011 Stroke Diseases 0.000 claims description 4
206010043118 Tardive Dyskinesia Diseases 0.000 claims description 4
239000002671 adjuvant Substances 0.000 claims description 4
230000003109 amnesic effect Effects 0.000 claims description 4
229910052799 carbon Inorganic materials 0.000 claims description 4
239000003085 diluting agent Substances 0.000 claims description 4
230000002996 emotional effect Effects 0.000 claims description 4
208000028867 ischemia Diseases 0.000 claims description 4
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
125000001424 substituent group Chemical group 0.000 claims description 4
230000001225 therapeutic effect Effects 0.000 claims description 4
201000010374 Down Syndrome Diseases 0.000 claims description 3
208000023105 Huntington disease Diseases 0.000 claims description 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
206010026749 Mania Diseases 0.000 claims description 3
208000005314 Multi-Infarct Dementia Diseases 0.000 claims description 3
206010033864 Paranoia Diseases 0.000 claims description 3
208000000323 Tourette Syndrome Diseases 0.000 claims description 3
201000004810 Vascular dementia Diseases 0.000 claims description 3
230000001154 acute effect Effects 0.000 claims description 3
208000029650 alcohol withdrawal Diseases 0.000 claims description 3
201000007201 aphasia Diseases 0.000 claims description 3
125000005843 halogen group Chemical group 0.000 claims description 3
208000011580 syndromic disease Diseases 0.000 claims description 3
CPHVPXAGOMENOX-UHFFFAOYSA-N (2-methylsulfanyl-4h-imidazol-5-yl)methanamine Chemical compound CSC1=NCC(CN)=N1 CPHVPXAGOMENOX-UHFFFAOYSA-N 0.000 claims description 2
125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 2
125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 2
UHFAWHKLDCGGOO-UHFFFAOYSA-N 1-ethyl-2-ethylsulfanyl-4h-imidazole-5-thione Chemical compound CCSC1=NCC(=S)N1CC UHFAWHKLDCGGOO-UHFFFAOYSA-N 0.000 claims description 2
KYEACNNYFNZCST-UHFFFAOYSA-N 1-methylpyrrolidine-2,5-dione Chemical compound CN1C(=O)CCC1=O KYEACNNYFNZCST-UHFFFAOYSA-N 0.000 claims description 2
QCXOIPHVHROGCG-UHFFFAOYSA-N 2,5-bis(methylsulfanyl)-4H-imidazole Chemical compound CSC=1N=C(CN=1)SC QCXOIPHVHROGCG-UHFFFAOYSA-N 0.000 claims description 2
HMIDAPVFGWMVLS-UHFFFAOYSA-N 2-methylsulfanyl-4h-imidazol-5-amine Chemical compound CSC1=NCC(N)=N1 HMIDAPVFGWMVLS-UHFFFAOYSA-N 0.000 claims description 2
RWSALGJDULZYJS-UHFFFAOYSA-N 3,5-dimethyl-1,3-thiazolidin-4-one Chemical compound CC1SCN(C)C1=O RWSALGJDULZYJS-UHFFFAOYSA-N 0.000 claims description 2
KKKHJOFUUPJCNK-UHFFFAOYSA-N 3-(4-pyrrolidin-1-ylbut-2-ynyl)imidazolidine-2,4-dione Chemical compound O=C1CNC(=O)N1CC#CCN1CCCC1 KKKHJOFUUPJCNK-UHFFFAOYSA-N 0.000 claims description 2
ZLWDIPYXBWMKJK-UHFFFAOYSA-N 3-but-2-ynylimidazolidine-2,4-dione Chemical compound CC#CCN1C(=O)CNC1=O ZLWDIPYXBWMKJK-UHFFFAOYSA-N 0.000 claims description 2
IWLAXCIQVRFHQW-UHFFFAOYSA-N 3-ethyl-1,3-oxazolidine-2,4-dione Chemical compound CCN1C(=O)COC1=O IWLAXCIQVRFHQW-UHFFFAOYSA-N 0.000 claims description 2
IAMKFIFYZHTKEN-UHFFFAOYSA-N 3-ethylimidazolidine-2,4-dithione Chemical compound CCN1C(=S)CNC1=S IAMKFIFYZHTKEN-UHFFFAOYSA-N 0.000 claims description 2
HPRXLMOZMACDQK-UHFFFAOYSA-N 4-ethylsulfanyl-1,5-dihydroimidazole-2-thione Chemical compound CCSC1=NC(=S)NC1 HPRXLMOZMACDQK-UHFFFAOYSA-N 0.000 claims description 2
FVKNKTHEUVXHKX-UHFFFAOYSA-N 4-methylsulfanylimidazolidine-2-thione Chemical compound CSC1CNC(=S)N1 FVKNKTHEUVXHKX-UHFFFAOYSA-N 0.000 claims description 2
DNPNXLYNSXZPGM-UHFFFAOYSA-N 4-sulfanylideneimidazolidin-2-one Chemical compound O=C1NCC(=S)N1 DNPNXLYNSXZPGM-UHFFFAOYSA-N 0.000 claims description 2
FGOXIPYQBXJWCS-UHFFFAOYSA-N 5-methoxy-2-methylsulfanyl-4h-imidazole Chemical compound COC1=NC(SC)=NC1 FGOXIPYQBXJWCS-UHFFFAOYSA-N 0.000 claims description 2
BDNZYSSJXXIKGT-UHFFFAOYSA-N 5-methyl-1,3-thiazolidin-4-one Chemical compound CC1SCNC1=O BDNZYSSJXXIKGT-UHFFFAOYSA-N 0.000 claims description 2
VYUGVBRTHROKDM-UHFFFAOYSA-N 5-methyl-1-oxo-1,3-thiazolidin-4-one Chemical compound CC1C(=O)NCS1=O VYUGVBRTHROKDM-UHFFFAOYSA-N 0.000 claims description 2
208000009829 Lewy Body Disease Diseases 0.000 claims description 2
201000002832 Lewy body dementia Diseases 0.000 claims description 2
DZSMWIFPAUKVLL-UHFFFAOYSA-N [2-(aminomethyl)-4h-imidazol-5-yl]methanamine Chemical compound NCC1=NC(CN)=NC1 DZSMWIFPAUKVLL-UHFFFAOYSA-N 0.000 claims description 2
125000005129 aryl carbonyl group Chemical group 0.000 claims description 2
229910052736 halogen Inorganic materials 0.000 claims description 2
150000002431 hydrogen Chemical class 0.000 claims description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
206010027175 memory impairment Diseases 0.000 claims description 2
COWNFYYYZFRNOY-UHFFFAOYSA-N oxazolidinedione Chemical compound O=C1COC(=O)N1 COWNFYYYZFRNOY-UHFFFAOYSA-N 0.000 claims description 2
229910052698 phosphorus Inorganic materials 0.000 claims description 2
125000004432 carbon atom Chemical group C* 0.000 claims 2
ATLYFUOZMXACPF-UHFFFAOYSA-N 1-ethyl-2-ethylsulfanyl-4h-imidazol-5-one Chemical compound CCSC1=NCC(=O)N1CC ATLYFUOZMXACPF-UHFFFAOYSA-N 0.000 claims 1
YRONCSMVZOWMDL-UHFFFAOYSA-N 1-ethyl-4h-imidazol-5-one Chemical compound CCN1C=NCC1=O YRONCSMVZOWMDL-UHFFFAOYSA-N 0.000 claims 1
MJODWMWEKBBINL-UHFFFAOYSA-N 3-tert-butylimidazolidine-2,4-dione Chemical compound CC(C)(C)N1C(=O)CNC1=O MJODWMWEKBBINL-UHFFFAOYSA-N 0.000 claims 1
125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
125000006620 amino-(C1-C6) alkyl group Chemical group 0.000 claims 1
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 255
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 145
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 126
238000005160 1H NMR spectroscopy Methods 0.000 description 101
241000700159 Rattus Species 0.000 description 97
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 89
239000000243 solution Substances 0.000 description 85
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 81
239000007787 solid Substances 0.000 description 65
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 64
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 63
239000000203 mixture Substances 0.000 description 62
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 60
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 59
229910001868 water Inorganic materials 0.000 description 59
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 57
DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 56
101710137189 Amyloid-beta A4 protein Proteins 0.000 description 55
102100022704 Amyloid-beta precursor protein Human genes 0.000 description 55
101710151993 Amyloid-beta precursor protein Proteins 0.000 description 55
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 54
239000000556 agonist Substances 0.000 description 52
YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 44
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 43
239000000047 product Substances 0.000 description 43
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 40
239000012458 free base Substances 0.000 description 39
235000019441 ethanol Nutrition 0.000 description 38
239000002904 solvent Substances 0.000 description 37
239000011541 reaction mixture Substances 0.000 description 36
ZSTLCHCDLIUXJE-ZGBAEQJLSA-N (2S,5S)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] hydrate dihydrochloride Chemical compound O.Cl.Cl.C1S[C@@H](C)O[C@@]21C(CC1)CCN1C2.C1S[C@@H](C)O[C@@]21C(CC1)CCN1C2 ZSTLCHCDLIUXJE-ZGBAEQJLSA-N 0.000 description 35
108010025020 Nerve Growth Factor Proteins 0.000 description 35
210000004027 cell Anatomy 0.000 description 34
239000000741 silica gel Substances 0.000 description 34
229910002027 silica gel Inorganic materials 0.000 description 34
238000012360 testing method Methods 0.000 description 34
PHOZOHFUXHPOCK-UHFFFAOYSA-N 2-ethyl-8-methyl-1-thia-4,8-diazaspiro[4.5]decan-3-one Chemical compound N1C(=O)C(CC)SC11CCN(C)CC1 PHOZOHFUXHPOCK-UHFFFAOYSA-N 0.000 description 33
102000015336 Nerve Growth Factor Human genes 0.000 description 33
229940053128 nerve growth factor Drugs 0.000 description 33
238000006243 chemical reaction Methods 0.000 description 32
238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 31
239000000284 extract Substances 0.000 description 30
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 29
238000000034 method Methods 0.000 description 29
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 27
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 27
230000002829 reductive effect Effects 0.000 description 27
238000010828 elution Methods 0.000 description 25
239000011780 sodium chloride Substances 0.000 description 25
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 24
229910021529 ammonia Inorganic materials 0.000 description 23
239000012528 membrane Substances 0.000 description 23
229940114079 arachidonic acid Drugs 0.000 description 22
235000021342 arachidonic acid Nutrition 0.000 description 22
230000001965 increasing effect Effects 0.000 description 22
150000003906 phosphoinositides Chemical class 0.000 description 22
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 21
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
102000034337 acetylcholine receptors Human genes 0.000 description 21
108020000715 acetylcholine receptors Proteins 0.000 description 21
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 21
239000003921 oil Substances 0.000 description 21
238000010992 reflux Methods 0.000 description 21
230000028327 secretion Effects 0.000 description 21
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 20
230000007062 hydrolysis Effects 0.000 description 20
238000006460 hydrolysis reaction Methods 0.000 description 20
239000002244 precipitate Substances 0.000 description 20
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 19
239000011877 solvent mixture Substances 0.000 description 19
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 18
210000004556 brain Anatomy 0.000 description 18
239000003446 ligand Substances 0.000 description 18
241000699670 Mus sp. Species 0.000 description 17
210000003710 cerebral cortex Anatomy 0.000 description 17
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 16
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
238000003556 assay Methods 0.000 description 16
230000002631 hypothermal effect Effects 0.000 description 16
102000013498 tau Proteins Human genes 0.000 description 16
108010026424 tau Proteins Proteins 0.000 description 16
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 15
108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 15
206010039424 Salivary hypersecretion Diseases 0.000 description 15
239000000706 filtrate Substances 0.000 description 15
239000003208 petroleum Substances 0.000 description 15
208000026451 salivation Diseases 0.000 description 15
239000011734 sodium Substances 0.000 description 15
206010021113 Hypothermia Diseases 0.000 description 14
238000004113 cell culture Methods 0.000 description 14
238000005406 washing Methods 0.000 description 14
230000001270 agonistic effect Effects 0.000 description 13
238000001704 evaporation Methods 0.000 description 13
230000008020 evaporation Effects 0.000 description 13
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 12
241001465754 Metazoa Species 0.000 description 12
230000004913 activation Effects 0.000 description 12
238000001994 activation Methods 0.000 description 12
229940079593 drug Drugs 0.000 description 12
150000003840 hydrochlorides Chemical class 0.000 description 12
238000001819 mass spectrum Methods 0.000 description 12
230000001404 mediated effect Effects 0.000 description 12
239000004031 partial agonist Substances 0.000 description 12
239000000843 powder Substances 0.000 description 12
108090000623 proteins and genes Proteins 0.000 description 12
102000005962 receptors Human genes 0.000 description 12
108020003175 receptors Proteins 0.000 description 12
238000005481 NMR spectroscopy Methods 0.000 description 11
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 11
238000002474 experimental method Methods 0.000 description 11
238000011534 incubation Methods 0.000 description 11
230000003551 muscarinic effect Effects 0.000 description 11
CANZROMYQDHYHR-UHFFFAOYSA-N oxotremorine M Chemical compound C[N+](C)(C)CC#CCN1CCCC1=O CANZROMYQDHYHR-UHFFFAOYSA-N 0.000 description 11
102000004169 proteins and genes Human genes 0.000 description 11
230000004044 response Effects 0.000 description 11
238000003756 stirring Methods 0.000 description 11
206010044565 Tremor Diseases 0.000 description 10
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 10
229960004373 acetylcholine Drugs 0.000 description 10
230000003542 behavioural effect Effects 0.000 description 10
210000003169 central nervous system Anatomy 0.000 description 10
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 10
229910000041 hydrogen chloride Inorganic materials 0.000 description 10
230000014759 maintenance of location Effects 0.000 description 10
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
230000003389 potentiating effect Effects 0.000 description 10
SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical group C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 description 10
ZGSNEAYELPMHGT-UHFFFAOYSA-N 8-methyl-2-oxo-1,3-diaza-8-azoniaspiro[4.5]dec-3-en-4-olate Chemical compound C1CN(C)CCC21C(=O)NC(=O)N2 ZGSNEAYELPMHGT-UHFFFAOYSA-N 0.000 description 9
ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 9
239000001099 ammonium carbonate Substances 0.000 description 9
235000012501 ammonium carbonate Nutrition 0.000 description 9
238000002425 crystallisation Methods 0.000 description 9
230000008025 crystallization Effects 0.000 description 9
235000006408 oxalic acid Nutrition 0.000 description 9
230000002093 peripheral effect Effects 0.000 description 9
239000000377 silicon dioxide Substances 0.000 description 9
229910000029 sodium carbonate Inorganic materials 0.000 description 9
235000017550 sodium carbonate Nutrition 0.000 description 9
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 9
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 8
206010012735 Diarrhoea Diseases 0.000 description 8
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 8
208000006550 Mydriasis Diseases 0.000 description 8
239000007864 aqueous solution Substances 0.000 description 8
AYJRCSIUFZENHW-UHFFFAOYSA-L barium carbonate Chemical compound [Ba+2].[O-]C([O-])=O AYJRCSIUFZENHW-UHFFFAOYSA-L 0.000 description 8
239000002585 base Substances 0.000 description 8
238000000586 desensitisation Methods 0.000 description 8
230000014511 neuron projection development Effects 0.000 description 8
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 8
UUFQTNFCRMXOAE-UHFFFAOYSA-N 1-methylmethylene Chemical compound C[CH] UUFQTNFCRMXOAE-UHFFFAOYSA-N 0.000 description 7
HUUPVABNAQUEJW-UHFFFAOYSA-N 1-methylpiperidin-4-one Chemical compound CN1CCC(=O)CC1 HUUPVABNAQUEJW-UHFFFAOYSA-N 0.000 description 7
PRROBIIYGSUPNR-UHFFFAOYSA-N 4-amino-1-methylpiperidin-1-ium-4-carboxylate Chemical compound CN1CCC(N)(C(O)=O)CC1 PRROBIIYGSUPNR-UHFFFAOYSA-N 0.000 description 7
101150041968 CDC13 gene Proteins 0.000 description 7
239000000908 ammonium hydroxide Substances 0.000 description 7
239000000872 buffer Substances 0.000 description 7
STECJAGHUSJQJN-VJQRDGCPSA-N chembl3084722 Chemical compound C1([C@@H](CO)C(=O)O[C@@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-VJQRDGCPSA-N 0.000 description 7
WTVNFKVGGUWHQC-UHFFFAOYSA-N decane-2,4-dione Chemical compound CCCCCCC(=O)CC(C)=O WTVNFKVGGUWHQC-UHFFFAOYSA-N 0.000 description 7
NPOMSUOUAZCMBL-UHFFFAOYSA-N dichloromethane;ethoxyethane Chemical compound ClCCl.CCOCC NPOMSUOUAZCMBL-UHFFFAOYSA-N 0.000 description 7
230000012010 growth Effects 0.000 description 7
230000003993 interaction Effects 0.000 description 7
239000012452 mother liquor Substances 0.000 description 7
230000003287 optical effect Effects 0.000 description 7
NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 7
229920006395 saturated elastomer Polymers 0.000 description 7
229960002646 scopolamine Drugs 0.000 description 7
238000012549 training Methods 0.000 description 7
HUTRESLXFRPBOW-UHFFFAOYSA-N 4-amino-1-methylpiperidine-4-carbonitrile Chemical compound CN1CCC(N)(C#N)CC1 HUTRESLXFRPBOW-UHFFFAOYSA-N 0.000 description 6
229930000680 A04AD01 - Scopolamine Natural products 0.000 description 6
STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 6
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 6
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 6
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
239000005557 antagonist Substances 0.000 description 6
230000002567 autonomic effect Effects 0.000 description 6
239000003153 chemical reaction reagent Substances 0.000 description 6
239000012043 crude product Substances 0.000 description 6
239000008188 pellet Substances 0.000 description 6
VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 6
230000026731 phosphorylation Effects 0.000 description 6
238000006366 phosphorylation reaction Methods 0.000 description 6
238000011533 pre-incubation Methods 0.000 description 6
230000009467 reduction Effects 0.000 description 6
230000000638 stimulation Effects 0.000 description 6
238000006467 substitution reaction Methods 0.000 description 6
239000000725 suspension Substances 0.000 description 6
CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 6
238000002560 therapeutic procedure Methods 0.000 description 6
239000008096 xylene Substances 0.000 description 6
PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical group CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 5
XJLDYKIEURAVBW-UHFFFAOYSA-N 3-decanone Chemical compound CCCCCCCC(=O)CC XJLDYKIEURAVBW-UHFFFAOYSA-N 0.000 description 5
JXUFHVUPZXLNGM-UHFFFAOYSA-N 4-hydroxy-1-methylpiperidine-4-carbonitrile Chemical compound CN1CCC(O)(C#N)CC1 JXUFHVUPZXLNGM-UHFFFAOYSA-N 0.000 description 5
QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 5
108091006027 G proteins Proteins 0.000 description 5
102000030782 GTP binding Human genes 0.000 description 5
108091000058 GTP-Binding Proteins 0.000 description 5
206010023644 Lacrimation increased Diseases 0.000 description 5
108010029485 Protein Isoforms Proteins 0.000 description 5
102000001708 Protein Isoforms Human genes 0.000 description 5
238000004458 analytical method Methods 0.000 description 5
210000001638 cerebellum Anatomy 0.000 description 5
238000004587 chromatography analysis Methods 0.000 description 5
239000012230 colorless oil Substances 0.000 description 5
238000004440 column chromatography Methods 0.000 description 5
230000008602 contraction Effects 0.000 description 5
WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 5
238000004821 distillation Methods 0.000 description 5
238000000605 extraction Methods 0.000 description 5
239000000499 gel Substances 0.000 description 5
150000001469 hydantoins Chemical class 0.000 description 5
238000003119 immunoblot Methods 0.000 description 5
230000001976 improved effect Effects 0.000 description 5
230000006872 improvement Effects 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
238000002347 injection Methods 0.000 description 5
239000007924 injection Substances 0.000 description 5
230000004317 lacrimation Effects 0.000 description 5
SEASIAOAVXWYDG-UHFFFAOYSA-N n-[(4-hydroxy-1-methylpiperidin-4-yl)methyl]acetamide Chemical compound CN1CCC(O)(CNC(C)=O)CC1 SEASIAOAVXWYDG-UHFFFAOYSA-N 0.000 description 5
230000000144 pharmacologic effect Effects 0.000 description 5
229910000027 potassium carbonate Inorganic materials 0.000 description 5
238000012545 processing Methods 0.000 description 5
230000001603 reducing effect Effects 0.000 description 5
DBUISQSWQYYXLB-UHFFFAOYSA-N (4-amino-1-methylpiperidin-4-yl)methanol Chemical compound CN1CCC(N)(CO)CC1 DBUISQSWQYYXLB-UHFFFAOYSA-N 0.000 description 4
GGYVTHJIUNGKFZ-UHFFFAOYSA-N 1-methylpiperidin-2-one Chemical compound CN1CCCCC1=O GGYVTHJIUNGKFZ-UHFFFAOYSA-N 0.000 description 4
VGGGBQVTSUMURJ-UHFFFAOYSA-N 2,8-dimethyl-1-thia-3,8-diazaspiro[4.5]dec-2-ene Chemical compound C1CN(C)CCC11SC(C)=NC1 VGGGBQVTSUMURJ-UHFFFAOYSA-N 0.000 description 4
VZSXBCQEJWUUJR-UHFFFAOYSA-N 3-ethyl-8-methyl-2-sulfanylidene-1,3,8-triazaspiro[4.5]decan-4-one Chemical compound O=C1N(CC)C(=S)NC11CCN(C)CC1 VZSXBCQEJWUUJR-UHFFFAOYSA-N 0.000 description 4
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
102000017927 CHRM1 Human genes 0.000 description 4
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
101150073075 Chrm1 gene Proteins 0.000 description 4
206010011953 Decreased activity Diseases 0.000 description 4
OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 4
208000026139 Memory disease Diseases 0.000 description 4
208000002193 Pain Diseases 0.000 description 4
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
206010038687 Respiratory distress Diseases 0.000 description 4
206010039897 Sedation Diseases 0.000 description 4
241000906446 Theraps Species 0.000 description 4
238000009825 accumulation Methods 0.000 description 4
230000009471 action Effects 0.000 description 4
239000008346 aqueous phase Substances 0.000 description 4
TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 4
230000009286 beneficial effect Effects 0.000 description 4
RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 4
230000002490 cerebral effect Effects 0.000 description 4
239000002026 chloroform extract Substances 0.000 description 4
230000001149 cognitive effect Effects 0.000 description 4
238000001816 cooling Methods 0.000 description 4
ZAJNGDIORYACQU-UHFFFAOYSA-N decan-2-one Chemical compound CCCCCCCCC(C)=O ZAJNGDIORYACQU-UHFFFAOYSA-N 0.000 description 4
239000003480 eluent Substances 0.000 description 4
DUYAAUVXQSMXQP-UHFFFAOYSA-N ethanethioic S-acid Chemical compound CC(S)=O DUYAAUVXQSMXQP-UHFFFAOYSA-N 0.000 description 4
230000035929 gnawing Effects 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 4
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
238000005259 measurement Methods 0.000 description 4
239000002480 mineral oil Substances 0.000 description 4
235000010446 mineral oil Nutrition 0.000 description 4
210000005036 nerve Anatomy 0.000 description 4
230000036407 pain Effects 0.000 description 4
230000037361 pathway Effects 0.000 description 4
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
CYQAYERJWZKYML-UHFFFAOYSA-N phosphorus pentasulfide Chemical compound S1P(S2)(=S)SP3(=S)SP1(=S)SP2(=S)S3 CYQAYERJWZKYML-UHFFFAOYSA-N 0.000 description 4
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 4
238000000746 purification Methods 0.000 description 4
230000036280 sedation Effects 0.000 description 4
JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 4
229960002317 succinimide Drugs 0.000 description 4
239000006228 supernatant Substances 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
HJVJWEVTPUHAFE-UHFFFAOYSA-N 2,8-dimethyl-1,3,8-triazaspiro[4.5]dec-2-ene Chemical compound C1CN(C)CCC11N=C(C)NC1 HJVJWEVTPUHAFE-UHFFFAOYSA-N 0.000 description 3
JUHFGHWNBYGKCW-UHFFFAOYSA-N 4-(aminomethyl)-1-methylpiperidin-4-ol Chemical compound CN1CCC(O)(CN)CC1 JUHFGHWNBYGKCW-UHFFFAOYSA-N 0.000 description 3
BVAGIEIKOUJDJC-UHFFFAOYSA-N 4-(ethylaminomethyl)-1-methylpiperidin-4-ol Chemical compound CCNCC1(O)CCN(C)CC1 BVAGIEIKOUJDJC-UHFFFAOYSA-N 0.000 description 3
229930003347 Atropine Natural products 0.000 description 3
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
206010010904 Convulsion Diseases 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 3
238000012347 Morris Water Maze Methods 0.000 description 3
PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 description 3
206010035039 Piloerection Diseases 0.000 description 3
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 3
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
150000001414 amino alcohols Chemical class 0.000 description 3
238000010171 animal model Methods 0.000 description 3
230000003042 antagnostic effect Effects 0.000 description 3
RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 3
229960000396 atropine Drugs 0.000 description 3
230000004071 biological effect Effects 0.000 description 3
125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 3
PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
QOPVNWQGBQYBBP-UHFFFAOYSA-N chloroethyl chloroformate Chemical compound CC(Cl)OC(Cl)=O QOPVNWQGBQYBBP-UHFFFAOYSA-N 0.000 description 3
230000036461 convulsion Effects 0.000 description 3
230000001054 cortical effect Effects 0.000 description 3
239000013058 crude material Substances 0.000 description 3
239000013078 crystal Substances 0.000 description 3
230000007812 deficiency Effects 0.000 description 3
MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
230000001747 exhibiting effect Effects 0.000 description 3
239000003102 growth factor Substances 0.000 description 3
WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
239000007788 liquid Substances 0.000 description 3
239000012280 lithium aluminium hydride Substances 0.000 description 3
229910052943 magnesium sulfate Inorganic materials 0.000 description 3
235000019341 magnesium sulphate Nutrition 0.000 description 3
239000002609 medium Substances 0.000 description 3
239000007922 nasal spray Substances 0.000 description 3
229940097496 nasal spray Drugs 0.000 description 3
210000002682 neurofibrillary tangle Anatomy 0.000 description 3
230000016273 neuron death Effects 0.000 description 3
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 3
239000012074 organic phase Substances 0.000 description 3
210000001428 peripheral nervous system Anatomy 0.000 description 3
PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 description 3
229960001697 physostigmine Drugs 0.000 description 3
230000005371 pilomotor reflex Effects 0.000 description 3
230000002035 prolonged effect Effects 0.000 description 3
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 3
238000012552 review Methods 0.000 description 3
239000000523 sample Substances 0.000 description 3
230000035939 shock Effects 0.000 description 3
229910052938 sodium sulfate Inorganic materials 0.000 description 3
235000011152 sodium sulphate Nutrition 0.000 description 3
239000012265 solid product Substances 0.000 description 3
238000001228 spectrum Methods 0.000 description 3
239000007858 starting material Substances 0.000 description 3
230000002195 synergetic effect Effects 0.000 description 3
229960001685 tacrine Drugs 0.000 description 3
YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 3
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 2
CMIBUZBMZCBCAT-HZPDHXFCSA-N (2r,3r)-2,3-bis[(4-methylbenzoyl)oxy]butanedioic acid Chemical compound C1=CC(C)=CC=C1C(=O)O[C@@H](C(O)=O)[C@H](C(O)=O)OC(=O)C1=CC=C(C)C=C1 CMIBUZBMZCBCAT-HZPDHXFCSA-N 0.000 description 2
CMIBUZBMZCBCAT-HOTGVXAUSA-N (2s,3s)-2,3-bis[(4-methylbenzoyl)oxy]butanedioic acid Chemical compound C1=CC(C)=CC=C1C(=O)O[C@H](C(O)=O)[C@@H](C(O)=O)OC(=O)C1=CC=C(C)C=C1 CMIBUZBMZCBCAT-HOTGVXAUSA-N 0.000 description 2
ZKMZPXWMMSBLNO-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-one Chemical compound C1CC2C(=O)CN1CC2 ZKMZPXWMMSBLNO-UHFFFAOYSA-N 0.000 description 2
WGMHMVLZFAJNOT-UHFFFAOYSA-N 1-ethoxyethylideneazanium;chloride Chemical compound [Cl-].CCOC(C)=[NH2+] WGMHMVLZFAJNOT-UHFFFAOYSA-N 0.000 description 2
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
UBRKDAVQCKZSPO-UHFFFAOYSA-N 11-[2-[2-(diethylaminomethyl)-1-piperidinyl]-1-oxoethyl]-5H-pyrido[2,3-b][1,4]benzodiazepin-6-one Chemical compound CCN(CC)CC1CCCCN1CC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 UBRKDAVQCKZSPO-UHFFFAOYSA-N 0.000 description 2
IENRHKXUQYTTSN-UHFFFAOYSA-N 2,8-dimethyl-1,4-dioxa-8-azaspiro[4.5]decan-3-one Chemical compound O1C(=O)C(C)OC11CCN(C)CC1 IENRHKXUQYTTSN-UHFFFAOYSA-N 0.000 description 2
OQNQYANDNUXYTC-UHFFFAOYSA-N 2,8-dimethyl-1-oxa-3,8-diazaspiro[4.5]dec-2-en-4-one Chemical compound C1CN(C)CCC21C(=O)N=C(C)O2 OQNQYANDNUXYTC-UHFFFAOYSA-N 0.000 description 2
IVCOMCSWJKKEEB-UHFFFAOYSA-N 2,8-dimethyl-1-oxa-4,8-diazaspiro[4.5]decan-3-one Chemical compound N1C(=O)C(C)OC11CCN(C)CC1 IVCOMCSWJKKEEB-UHFFFAOYSA-N 0.000 description 2
RDKPCIMNMZRNEA-UHFFFAOYSA-N 2,8-dimethyl-1-oxo-1$l^{4}-thia-4,8-diazaspiro[4.5]decan-3-one Chemical compound O=S1C(C)C(=O)NC11CCN(C)CC1 RDKPCIMNMZRNEA-UHFFFAOYSA-N 0.000 description 2
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
LFILQFFBSPEZJH-UHFFFAOYSA-N 2-ethyl-4,8-dimethyl-1-thia-4,8-diazaspiro[4.5]decan-3-one Chemical compound CN1C(=O)C(CC)SC11CCN(C)CC1 LFILQFFBSPEZJH-UHFFFAOYSA-N 0.000 description 2
HXQRXARTBTVIRH-UHFFFAOYSA-N 2-n,4-n,8-trimethyl-1,3,8-triazaspiro[4.5]deca-1,3-diene-2,4-diamine Chemical compound CNC1=NC(NC)=NC11CCN(C)CC1 HXQRXARTBTVIRH-UHFFFAOYSA-N 0.000 description 2
CFPHMAVQAJGVPV-UHFFFAOYSA-N 2-sulfanylbutanoic acid Chemical compound CCC(S)C(O)=O CFPHMAVQAJGVPV-UHFFFAOYSA-N 0.000 description 2
BLSUNHNPQHEFGK-UHFFFAOYSA-N 3-ethyl-8-methyl-1,3,8-triazaspiro[4.5]dec-1-en-4-one Chemical compound O=C1N(CC)C=NC11CCN(C)CC1 BLSUNHNPQHEFGK-UHFFFAOYSA-N 0.000 description 2
DFXMJZITESLWIU-UHFFFAOYSA-N 3-ethyl-8-methyl-1,3,8-triazaspiro[4.5]decane-2,4-dithione Chemical compound S=C1N(CC)C(=S)NC11CCN(C)CC1 DFXMJZITESLWIU-UHFFFAOYSA-N 0.000 description 2
ZFLHJBJOJKIGEN-UHFFFAOYSA-N 3-ethyl-8-methyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one Chemical compound O1C(=O)N(CC)CC11CCN(C)CC1 ZFLHJBJOJKIGEN-UHFFFAOYSA-N 0.000 description 2
JVCUVZJRDGGVJT-UHFFFAOYSA-N 3-ethyl-8-methyl-1-oxa-3,8-diazaspiro[4.5]decane-2,4-dione Chemical compound O=C1N(CC)C(=O)OC11CCN(C)CC1 JVCUVZJRDGGVJT-UHFFFAOYSA-N 0.000 description 2
YWGPWCCMWXQVSL-UHFFFAOYSA-N 3-ethyl-8-methyl-1-oxa-4,8-diazaspiro[4.5]decane Chemical compound N1C(CC)COC11CCN(C)CC1 YWGPWCCMWXQVSL-UHFFFAOYSA-N 0.000 description 2
SSQPQLBKDXSGED-UHFFFAOYSA-N 3-ethyl-8-methyl-1-oxa-4-thia-8-azaspiro[4.5]decan-2-one Chemical compound O1C(=O)C(CC)SC11CCN(C)CC1 SSQPQLBKDXSGED-UHFFFAOYSA-N 0.000 description 2
RQGXGXMPGUFTBG-UHFFFAOYSA-N 3-prop-2-ynyl-1,3,8-triazaspiro[4.5]decane-2,4-dione Chemical compound O=C1N(CC#C)C(=O)NC11CCNCC1 RQGXGXMPGUFTBG-UHFFFAOYSA-N 0.000 description 2
CGFRCBQIPHFZJG-UHFFFAOYSA-N 4-(aminomethyl)-1-methylpiperidin-4-amine Chemical compound CN1CCC(N)(CN)CC1 CGFRCBQIPHFZJG-UHFFFAOYSA-N 0.000 description 2
XCTPMBZCYFICBI-UHFFFAOYSA-N 4-(aminomethyl)-1-methylpiperidin-4-ol;hydrochloride Chemical compound Cl.CN1CCC(O)(CN)CC1 XCTPMBZCYFICBI-UHFFFAOYSA-N 0.000 description 2
NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 description 2
VMJKYXYPUPSWMA-UHFFFAOYSA-N 4-hydroxy-1-methylpiperidine-4-carboxamide Chemical compound CN1CCC(O)(C(N)=O)CC1 VMJKYXYPUPSWMA-UHFFFAOYSA-N 0.000 description 2
YNRWQRBUPXXCGI-UHFFFAOYSA-N 5-methyl-2-(1-methylpiperidin-4-yl)-1,3-thiazolidine-4-thione Chemical compound N1C(=S)C(C)SC1C1CCN(C)CC1 YNRWQRBUPXXCGI-UHFFFAOYSA-N 0.000 description 2
IODIRNHGMQEBBK-UHFFFAOYSA-N 8-methyl-1-oxa-3,8-diazaspiro[4.5]decane-2,4-dione Chemical compound C1CN(C)CCC21C(=O)NC(=O)O2 IODIRNHGMQEBBK-UHFFFAOYSA-N 0.000 description 2
QEZXDCADJYRSJC-UHFFFAOYSA-N 8-methyl-1-oxa-3,8-diazaspiro[4.5]decane-2-thione Chemical compound C1CN(C)CCC11OC(=S)NC1 QEZXDCADJYRSJC-UHFFFAOYSA-N 0.000 description 2
JXARKRZIIDQXBT-UHFFFAOYSA-N 8-methyl-4-methylsulfanyl-1,3,8-triazaspiro[4.5]dec-3-ene-2-thione Chemical compound CSC1=NC(=S)NC11CCN(C)CC1 JXARKRZIIDQXBT-UHFFFAOYSA-N 0.000 description 2
206010002091 Anaesthesia Diseases 0.000 description 2
208000020925 Bipolar disease Diseases 0.000 description 2
108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 2
102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 2
241000700199 Cavia porcellus Species 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
208000014094 Dystonic disease Diseases 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
201000011240 Frontotemporal dementia Diseases 0.000 description 2
VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 description 2
UQABYHGXWYXDTK-UUOKFMHZSA-N GppNP Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)NP(O)(O)=O)[C@@H](O)[C@H]1O UQABYHGXWYXDTK-UUOKFMHZSA-N 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
206010024264 Lethargy Diseases 0.000 description 2
GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 2
GZHFODJQISUKAY-UHFFFAOYSA-N Methantheline Chemical compound C1=CC=C2C(C(=O)OCC[N+](C)(CC)CC)C3=CC=CC=C3OC2=C1 GZHFODJQISUKAY-UHFFFAOYSA-N 0.000 description 2
102000029749 Microtubule Human genes 0.000 description 2
108091022875 Microtubule Proteins 0.000 description 2
229940121948 Muscarinic receptor antagonist Drugs 0.000 description 2
ZSBDPRIWBYHIAF-UHFFFAOYSA-N N-acetyl-acetamide Natural products CC(=O)NC(C)=O ZSBDPRIWBYHIAF-UHFFFAOYSA-N 0.000 description 2
102000007072 Nerve Growth Factors Human genes 0.000 description 2
239000000020 Nitrocellulose Substances 0.000 description 2
PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 2
208000008469 Peptic Ulcer Diseases 0.000 description 2
208000000609 Pick Disease of the Brain Diseases 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
VVWYOYDLCMFIEM-UHFFFAOYSA-N Propantheline Chemical compound C1=CC=C2C(C(=O)OCC[N+](C)(C(C)C)C(C)C)C3=CC=CC=C3OC2=C1 VVWYOYDLCMFIEM-UHFFFAOYSA-N 0.000 description 2
229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
239000007868 Raney catalyst Substances 0.000 description 2
229910000564 Raney nickel Inorganic materials 0.000 description 2
WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
102000005157 Somatostatin Human genes 0.000 description 2
108010056088 Somatostatin Proteins 0.000 description 2
229910000831 Steel Inorganic materials 0.000 description 2
206010047700 Vomiting Diseases 0.000 description 2
JASZLXKQDWOZAC-UHFFFAOYSA-N [4-(acetylcarbamoyl)-1-methylpiperidin-4-yl] acetate Chemical compound CN1CCC(C(=O)NC(C)=O)(OC(C)=O)CC1 JASZLXKQDWOZAC-UHFFFAOYSA-N 0.000 description 2
AMDQXGZAKPTOJZ-UHFFFAOYSA-N [4-(ethylamino)-1-methylpiperidin-4-yl]methanol Chemical compound CCNC1(CO)CCN(C)CC1 AMDQXGZAKPTOJZ-UHFFFAOYSA-N 0.000 description 2
230000021736 acetylation Effects 0.000 description 2
238000006640 acetylation reaction Methods 0.000 description 2
238000005903 acid hydrolysis reaction Methods 0.000 description 2
230000003213 activating effect Effects 0.000 description 2
102000030621 adenylate cyclase Human genes 0.000 description 2
108060000200 adenylate cyclase Proteins 0.000 description 2
230000032683 aging Effects 0.000 description 2
125000003545 alkoxy group Chemical group 0.000 description 2
150000001408 amides Chemical class 0.000 description 2
OYTKINVCDFNREN-UHFFFAOYSA-N amifampridine Chemical compound NC1=CC=NC=C1N OYTKINVCDFNREN-UHFFFAOYSA-N 0.000 description 2
229960004012 amifampridine Drugs 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
229960000836 amitriptyline Drugs 0.000 description 2
KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 2
235000019270 ammonium chloride Nutrition 0.000 description 2
230000003941 amyloidogenesis Effects 0.000 description 2
230000037005 anaesthesia Effects 0.000 description 2
ZXNRTKGTQJPIJK-UHFFFAOYSA-N aniracetam Chemical compound C1=CC(OC)=CC=C1C(=O)N1C(=O)CCC1 ZXNRTKGTQJPIJK-UHFFFAOYSA-N 0.000 description 2
229960000793 aniracetam Drugs 0.000 description 2
230000001022 anti-muscarinic effect Effects 0.000 description 2
238000013459 approach Methods 0.000 description 2
208000006673 asthma Diseases 0.000 description 2
210000003050 axon Anatomy 0.000 description 2
230000003376 axonal effect Effects 0.000 description 2
ZUDYPQRUOYEARG-UHFFFAOYSA-L barium(2+);dihydroxide;octahydrate Chemical compound O.O.O.O.O.O.O.O.[OH-].[OH-].[Ba+2] ZUDYPQRUOYEARG-UHFFFAOYSA-L 0.000 description 2
230000006399 behavior Effects 0.000 description 2
UHOVQNZJYSORNB-MZWXYZOWSA-N benzene-d6 Chemical compound [2H]C1=C([2H])C([2H])=C([2H])C([2H])=C1[2H] UHOVQNZJYSORNB-MZWXYZOWSA-N 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
208000028683 bipolar I disease Diseases 0.000 description 2
210000005013 brain tissue Anatomy 0.000 description 2
229940077737 brain-derived neurotrophic factor Drugs 0.000 description 2
YBCNXCRZPWQOBR-WVHCHWADSA-N butylscopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)CCCC)=CC=CC=C1 YBCNXCRZPWQOBR-WVHCHWADSA-N 0.000 description 2
230000001593 cAMP accumulation Effects 0.000 description 2
150000001721 carbon Chemical group 0.000 description 2
229910002092 carbon dioxide Inorganic materials 0.000 description 2
239000003054 catalyst Substances 0.000 description 2
125000002091 cationic group Chemical group 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
230000008859 change Effects 0.000 description 2
PIPAJLPNWZMYQA-KNCRFDSUSA-N chembl1187724 Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N+]2(C)C)C(=O)C(CO)C1=CC=CC=C1 PIPAJLPNWZMYQA-KNCRFDSUSA-N 0.000 description 2
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
229960001231 choline Drugs 0.000 description 2
239000000544 cholinesterase inhibitor Substances 0.000 description 2
208000010877 cognitive disease Diseases 0.000 description 2
239000003636 conditioned culture medium Substances 0.000 description 2
ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 2
239000010779 crude oil Substances 0.000 description 2
YZEIFGNUDSVADO-UHFFFAOYSA-N dec-1-en-4-one Chemical compound CCCCCCC(=O)CC=C YZEIFGNUDSVADO-UHFFFAOYSA-N 0.000 description 2
YHHHHJCAVQSFMJ-UHFFFAOYSA-N deca-1,3-diene Chemical compound CCCCCCC=CC=C YHHHHJCAVQSFMJ-UHFFFAOYSA-N 0.000 description 2
230000008021 deposition Effects 0.000 description 2
238000001514 detection method Methods 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
238000010494 dissociation reaction Methods 0.000 description 2
230000005593 dissociations Effects 0.000 description 2
238000001378 electrochemiluminescence detection Methods 0.000 description 2
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
HBNYJWAFDZLWRS-UHFFFAOYSA-N ethyl isothiocyanate Chemical compound CCN=C=S HBNYJWAFDZLWRS-UHFFFAOYSA-N 0.000 description 2
229960004979 fampridine Drugs 0.000 description 2
238000001914 filtration Methods 0.000 description 2
239000005350 fused silica glass Substances 0.000 description 2
229940015042 glycopyrrolate Drugs 0.000 description 2
210000003128 head Anatomy 0.000 description 2
239000005457 ice water Substances 0.000 description 2
MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 2
229960004801 imipramine Drugs 0.000 description 2
BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 2
230000001771 impaired effect Effects 0.000 description 2
239000012535 impurity Substances 0.000 description 2
230000006698 induction Effects 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
239000004310 lactic acid Substances 0.000 description 2
235000014655 lactic acid Nutrition 0.000 description 2
239000000787 lecithin Substances 0.000 description 2
229940067606 lecithin Drugs 0.000 description 2
235000010445 lecithin Nutrition 0.000 description 2
GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 2
108010052968 leupeptin Proteins 0.000 description 2
KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
239000000463 material Substances 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
229960001470 methantheline Drugs 0.000 description 2
VUQUOGPMUUJORT-UHFFFAOYSA-N methyl 4-methylbenzenesulfonate Chemical compound COS(=O)(=O)C1=CC=C(C)C=C1 VUQUOGPMUUJORT-UHFFFAOYSA-N 0.000 description 2
210000004688 microtubule Anatomy 0.000 description 2
LDMWSLGGVTVJPG-UHFFFAOYSA-N minaprine Chemical compound CC1=CC(C=2C=CC=CC=2)=NN=C1NCCN1CCOCC1 LDMWSLGGVTVJPG-UHFFFAOYSA-N 0.000 description 2
229960004758 minaprine Drugs 0.000 description 2
239000002808 molecular sieve Substances 0.000 description 2
239000003149 muscarinic antagonist Substances 0.000 description 2
230000001537 neural effect Effects 0.000 description 2
210000002569 neuron Anatomy 0.000 description 2
238000006386 neutralization reaction Methods 0.000 description 2
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 2
229960002715 nicotine Drugs 0.000 description 2
229920001220 nitrocellulos Polymers 0.000 description 2
239000012299 nitrogen atmosphere Substances 0.000 description 2
229910000069 nitrogen hydride Inorganic materials 0.000 description 2
229960001158 nortriptyline Drugs 0.000 description 2
206010030899 opisthotonus Diseases 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
150000002917 oxazolidines Chemical class 0.000 description 2
KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
IHLAQQPQKRMGSS-UHFFFAOYSA-N oxiracetam Chemical compound NC(=O)CN1CC(O)CC1=O IHLAQQPQKRMGSS-UHFFFAOYSA-N 0.000 description 2
229960001227 oxiracetam Drugs 0.000 description 2
239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
239000012071 phase Substances 0.000 description 2
239000000902 placebo Substances 0.000 description 2
229940068196 placebo Drugs 0.000 description 2
239000001103 potassium chloride Substances 0.000 description 2
235000011164 potassium chloride Nutrition 0.000 description 2
ZULJGOSFKWFVRX-UHFFFAOYSA-N pramiracetam Chemical compound CC(C)N(C(C)C)CCNC(=O)CN1CCCC1=O ZULJGOSFKWFVRX-UHFFFAOYSA-N 0.000 description 2
229960003389 pramiracetam Drugs 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
239000000651 prodrug Substances 0.000 description 2
229940002612 prodrug Drugs 0.000 description 2
230000001737 promoting effect Effects 0.000 description 2
229960000697 propantheline Drugs 0.000 description 2
230000009822 protein phosphorylation Effects 0.000 description 2
JUJWROOIHBZHMG-RALIUCGRSA-N pyridine-d5 Chemical compound [2H]C1=NC([2H])=C([2H])C([2H])=C1[2H] JUJWROOIHBZHMG-RALIUCGRSA-N 0.000 description 2
238000007142 ring opening reaction Methods 0.000 description 2
210000003296 saliva Anatomy 0.000 description 2
230000003248 secreting effect Effects 0.000 description 2
MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 2
238000000926 separation method Methods 0.000 description 2
230000019491 signal transduction Effects 0.000 description 2
230000011664 signaling Effects 0.000 description 2
238000004088 simulation Methods 0.000 description 2
URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 2
229960000553 somatostatin Drugs 0.000 description 2
238000013222 sprague-dawley male rat Methods 0.000 description 2
229910001220 stainless steel Inorganic materials 0.000 description 2
239000010935 stainless steel Substances 0.000 description 2
239000010959 steel Substances 0.000 description 2
KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
150000003549 thiazolines Chemical class 0.000 description 2
238000001665 trituration Methods 0.000 description 2
QQXLDOJGLXJCSE-KNVOCYPGSA-N tropinone Chemical compound C1C(=O)C[C@H]2CC[C@@H]1N2C QQXLDOJGLXJCSE-KNVOCYPGSA-N 0.000 description 2
230000008673 vomiting Effects 0.000 description 2
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
ICZHJFWIOPYQCA-OAHLLOKOSA-N (1r)-1-anthracen-9-yl-2,2,2-trifluoroethanol Chemical compound C1=CC=C2C([C@@H](O)C(F)(F)F)=C(C=CC=C3)C3=CC2=C1 ICZHJFWIOPYQCA-OAHLLOKOSA-N 0.000 description 1
YYMCYJLIYNNOMK-MEKDEQNOSA-N (1r,5s)-8-azabicyclo[3.2.1]octan-3-ol Chemical compound C1C(O)C[C@@H]2CC[C@H]1N2 YYMCYJLIYNNOMK-MEKDEQNOSA-N 0.000 description 1
PHOZOHFUXHPOCK-QMMMGPOBSA-N (2s)-2-ethyl-8-methyl-1-thia-4,8-diazaspiro[4.5]decan-3-one Chemical compound N1C(=O)[C@H](CC)SC11CCN(C)CC1 PHOZOHFUXHPOCK-QMMMGPOBSA-N 0.000 description 1
SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
HXKKHQJGJAFBHI-UHFFFAOYSA-N 1-aminopropan-2-ol Chemical compound CC(O)CN HXKKHQJGJAFBHI-UHFFFAOYSA-N 0.000 description 1
YEEZJFPQHRGYKN-UHFFFAOYSA-N 1-ethyl-8-methyl-3-oxa-1,8-diazaspiro[4.5]decan-2-one Chemical compound CCN1C(=O)OCC11CCN(C)CC1 YEEZJFPQHRGYKN-UHFFFAOYSA-N 0.000 description 1
XIKAWPIDTFYWLQ-UHFFFAOYSA-N 1-methyl-4-(nitromethyl)piperidin-4-ol Chemical compound CN1CCC(O)(C[N+]([O-])=O)CC1 XIKAWPIDTFYWLQ-UHFFFAOYSA-N 0.000 description 1
VJCQJLZYYKTLNA-UHFFFAOYSA-N 1-methyl-4-(nitromethyl)piperidin-4-ol;hydrochloride Chemical compound Cl.CN1CCC(O)(C[N+]([O-])=O)CC1 VJCQJLZYYKTLNA-UHFFFAOYSA-N 0.000 description 1
RMHMFHUVIITRHF-RLXJOQACSA-N 11-[2-[4-(tritritiomethyl)piperazin-1-yl]acetyl]-5h-pyrido[2,3-b][1,4]benzodiazepin-6-one Chemical compound C1CN(C([3H])([3H])[3H])CCN1CC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 RMHMFHUVIITRHF-RLXJOQACSA-N 0.000 description 1
QUAAWVSDJQPGBI-UHFFFAOYSA-N 2,8-dimethyl-1-thia-4,8-diazaspiro[4.5]decan-3-one Chemical compound N1C(=O)C(C)SC11CCN(C)CC1 QUAAWVSDJQPGBI-UHFFFAOYSA-N 0.000 description 1
IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
JCBPETKZIGVZRE-UHFFFAOYSA-N 2-aminobutan-1-ol Chemical compound CCC(N)CO JCBPETKZIGVZRE-UHFFFAOYSA-N 0.000 description 1
MLIREBYILWEBDM-UHFFFAOYSA-M 2-cyanoacetate Chemical compound [O-]C(=O)CC#N MLIREBYILWEBDM-UHFFFAOYSA-M 0.000 description 1
ZFWFRTVIIMTOLY-UHFFFAOYSA-N 2-isothiocyanato-2-methylpropane Chemical compound CC(C)(C)N=C=S ZFWFRTVIIMTOLY-UHFFFAOYSA-N 0.000 description 1
125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
UEKVEPQDQOYBHB-UHFFFAOYSA-N 3,8-dimethyl-1,3,8-triazaspiro[4.5]decane-2,4-dione Chemical compound O=C1N(C)C(=O)NC11CCN(C)CC1 UEKVEPQDQOYBHB-UHFFFAOYSA-N 0.000 description 1
BAQCETYCWHELLE-UHFFFAOYSA-N 3-but-2-ynyl-8-methyl-1,3,8-triazaspiro[4.5]decane-2,4-dione Chemical compound O=C1N(CC#CC)C(=O)NC11CCN(C)CC1 BAQCETYCWHELLE-UHFFFAOYSA-N 0.000 description 1
OOHDXSAIMKUZKO-UHFFFAOYSA-N 3-ethyl-1,3,8-triazaspiro[4.5]decane-2,4-dione Chemical compound O=C1N(CC)C(=O)NC11CCNCC1 OOHDXSAIMKUZKO-UHFFFAOYSA-N 0.000 description 1
WGQVJSXITOHEFH-UHFFFAOYSA-N 3-ethyl-2-ethylsulfanyl-8-methyl-1,3,8-triazaspiro[4.5]dec-1-en-4-one Chemical compound O=C1N(CC)C(SCC)=NC11CCN(C)CC1 WGQVJSXITOHEFH-UHFFFAOYSA-N 0.000 description 1
VUCNEYMTGQIFLB-UHFFFAOYSA-N 3-ethyl-2-ethylsulfanyl-8-methyl-1,3,8-triazaspiro[4.5]dec-1-ene-4-thione Chemical compound S=C1N(CC)C(SCC)=NC11CCN(C)CC1 VUCNEYMTGQIFLB-UHFFFAOYSA-N 0.000 description 1
QGERPENHDRAOCC-UHFFFAOYSA-N 3-ethyl-8-methyl-4-sulfanylidene-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound S=C1N(CC)C(=O)NC11CCN(C)CC1 QGERPENHDRAOCC-UHFFFAOYSA-N 0.000 description 1
NLITZISVKPYCPP-UHFFFAOYSA-N 3-methyl-1,3,8-triazaspiro[4.5]decane-2,4-dione Chemical compound O=C1N(C)C(=O)NC11CCNCC1 NLITZISVKPYCPP-UHFFFAOYSA-N 0.000 description 1
RZBCTZRJDQGMJU-UHFFFAOYSA-N 3-methyl-1-oxa-4-thia-8-azaspiro[4.5]decan-2-one Chemical compound O1C(=O)C(C)SC11CCNCC1 RZBCTZRJDQGMJU-UHFFFAOYSA-N 0.000 description 1
ZFWQGQXGZQXESQ-UHFFFAOYSA-N 4-(butylamino)-8-methyl-1,3,8-triazaspiro[4.5]dec-3-ene-2-thione Chemical compound CCCCN=C1NC(=S)NC11CCN(C)CC1 ZFWQGQXGZQXESQ-UHFFFAOYSA-N 0.000 description 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
JEYBTWQZMFZEEV-UHFFFAOYSA-N 4-acetamido-1-methylpiperidine-4-carboxamide Chemical compound CN1CCC(C(N)=O)(NC(C)=O)CC1 JEYBTWQZMFZEEV-UHFFFAOYSA-N 0.000 description 1
WKKXQBIARFVHHE-UHFFFAOYSA-N 4-amino-1-methylpiperidine-4-carboxamide Chemical compound CN1CCC(N)(C(N)=O)CC1 WKKXQBIARFVHHE-UHFFFAOYSA-N 0.000 description 1
LVSPDZAGCBEQAV-UHFFFAOYSA-N 4-chloronaphthalen-1-ol Chemical compound C1=CC=C2C(O)=CC=C(Cl)C2=C1 LVSPDZAGCBEQAV-UHFFFAOYSA-N 0.000 description 1
NGNNFDYHJKDHJN-UHFFFAOYSA-N 5-aminoimidazole-2,4-dione Chemical class N=C1NC(=O)NC1=O NGNNFDYHJKDHJN-UHFFFAOYSA-N 0.000 description 1
ZFGWGBFPJIIWDY-UHFFFAOYSA-N 8-methyl-1,3,8-triazaspiro[4.5]decane-2,4-dithione Chemical compound C1CN(C)CCC21C(=S)NC(=S)N2 ZFGWGBFPJIIWDY-UHFFFAOYSA-N 0.000 description 1
AXETUYCJPPQEGQ-UHFFFAOYSA-N 8-methyl-2,4-bis(methylsulfanyl)-1,3,8-triazaspiro[4.5]deca-1,3-diene Chemical compound CSC1=NC(SC)=NC11CCN(C)CC1 AXETUYCJPPQEGQ-UHFFFAOYSA-N 0.000 description 1
DCCBTJHJSAORLC-UHFFFAOYSA-N 8-methyl-2-methylsulfanyl-1,3,8-triazaspiro[4.5]dec-1-en-4-one Chemical compound O=C1NC(SC)=NC11CCN(C)CC1 DCCBTJHJSAORLC-UHFFFAOYSA-N 0.000 description 1
RCHWTXCXKFTLDI-UHFFFAOYSA-N 8-methyl-2-methylsulfanyl-1,3,8-triazaspiro[4.5]deca-1,3-dien-4-amine Chemical compound NC1=NC(SC)=NC11CCN(C)CC1 RCHWTXCXKFTLDI-UHFFFAOYSA-N 0.000 description 1
AMKKUUQTADTHAT-UHFFFAOYSA-N 8-methyl-3-(4-pyrrolidin-1-ylbut-2-ynyl)-1,3,8-triazaspiro[4.5]decane-2,4-dione Chemical compound C1CN(C)CCC21C(=O)N(CC#CCN1CCCC1)C(=O)N2 AMKKUUQTADTHAT-UHFFFAOYSA-N 0.000 description 1
108010013043 Acetylesterase Proteins 0.000 description 1
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
206010001540 Akathisia Diseases 0.000 description 1
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
239000005695 Ammonium acetate Substances 0.000 description 1
208000000044 Amnesia Diseases 0.000 description 1
208000037259 Amyloid Plaque Diseases 0.000 description 1
102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 1
108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 1
102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
108010039627 Aprotinin Proteins 0.000 description 1
206010003497 Asphyxia Diseases 0.000 description 1
102000007527 Autoreceptors Human genes 0.000 description 1
108010071131 Autoreceptors Proteins 0.000 description 1
230000007082 Aβ accumulation Effects 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
238000009010 Bradford assay Methods 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
CNSUBJLHAWCWDQ-UHFFFAOYSA-N C(C)(=O)NC1(CCN(CC1)C)CO.C(C)NC1(CCN(CC1)C)CO Chemical compound C(C)(=O)NC1(CCN(CC1)C)CO.C(C)NC1(CCN(CC1)C)CO CNSUBJLHAWCWDQ-UHFFFAOYSA-N 0.000 description 1
102000017925 CHRM3 Human genes 0.000 description 1
101150060249 CHRM3 gene Proteins 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
241000283707 Capra Species 0.000 description 1
108091006146 Channels Proteins 0.000 description 1
102100032404 Cholinesterase Human genes 0.000 description 1
101710083761 Cholinesterase Proteins 0.000 description 1
101710178035 Chorismate synthase 2 Proteins 0.000 description 1
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
208000028698 Cognitive impairment Diseases 0.000 description 1
MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
206010011703 Cyanosis Diseases 0.000 description 1
101710152694 Cysteine synthase 2 Proteins 0.000 description 1
208000031124 Dementia Alzheimer type Diseases 0.000 description 1
206010054089 Depressive symptom Diseases 0.000 description 1
OIFBSDVPJOWBCH-UHFFFAOYSA-N Diethyl carbonate Chemical compound CCOC(=O)OCC OIFBSDVPJOWBCH-UHFFFAOYSA-N 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
108090000371 Esterases Proteins 0.000 description 1
239000005977 Ethylene Substances 0.000 description 1
208000018522 Gastrointestinal disease Diseases 0.000 description 1
208000010412 Glaucoma Diseases 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
238000001321 HNCO Methods 0.000 description 1
SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000891579 Homo sapiens Microtubule-associated protein tau Proteins 0.000 description 1
101000718497 Homo sapiens Protein AF-10 Proteins 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
206010020651 Hyperkinesia Diseases 0.000 description 1
208000000269 Hyperkinesis Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
208000001953 Hypotension Diseases 0.000 description 1
OWIKHYCFFJSOEH-UHFFFAOYSA-N Isocyanic acid Chemical compound N=C=O OWIKHYCFFJSOEH-UHFFFAOYSA-N 0.000 description 1
DHUZAAUGHUHIDS-ONEGZZNKSA-N Isomyristicin Chemical compound COC1=CC(\C=C\C)=CC2=C1OCO2 DHUZAAUGHUHIDS-ONEGZZNKSA-N 0.000 description 1
241001397173 Kali <angiosperm> Species 0.000 description 1
239000001358 L(+)-tartaric acid Substances 0.000 description 1
235000011002 L(+)-tartaric acid Nutrition 0.000 description 1
FEWJPZIEWOKRBE-LWMBPPNESA-N L-(+)-Tartaric acid Natural products OC(=O)[C@@H](O)[C@H](O)C(O)=O FEWJPZIEWOKRBE-LWMBPPNESA-N 0.000 description 1
229940126083 M3 antagonist Drugs 0.000 description 1
LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 1
PQMWYJDJHJQZDE-UHFFFAOYSA-M Methantheline bromide Chemical compound [Br-].C1=CC=C2C(C(=O)OCC[N+](C)(CC)CC)C3=CC=CC=C3OC2=C1 PQMWYJDJHJQZDE-UHFFFAOYSA-M 0.000 description 1
102000009664 Microtubule-Associated Proteins Human genes 0.000 description 1
108010020004 Microtubule-Associated Proteins Proteins 0.000 description 1
102100036617 Monoacylglycerol lipase ABHD2 Human genes 0.000 description 1
208000016285 Movement disease Diseases 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
FLVIGYVXZHLUHP-UHFFFAOYSA-N N,N'-diethylthiourea Chemical compound CCNC(=S)NCC FLVIGYVXZHLUHP-UHFFFAOYSA-N 0.000 description 1
QQXLDOJGLXJCSE-UHFFFAOYSA-N N-methylnortropinone Natural products C1C(=O)CC2CCC1N2C QQXLDOJGLXJCSE-UHFFFAOYSA-N 0.000 description 1
YYMCYJLIYNNOMK-UHFFFAOYSA-N N-normethyltropine Natural products C1C(O)CC2CCC1N2 YYMCYJLIYNNOMK-UHFFFAOYSA-N 0.000 description 1
108091008604 NGF receptors Proteins 0.000 description 1
239000007832 Na2SO4 Substances 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 1
102100029268 Neurotrophin-3 Human genes 0.000 description 1
102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 1
108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 1
RSDOPYMFZBJHRL-UHFFFAOYSA-N Oxotremorine Chemical compound O=C1CCCN1CC#CCN1CCCC1 RSDOPYMFZBJHRL-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
206010033557 Palpitations Diseases 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
206010033799 Paralysis Diseases 0.000 description 1
208000037273 Pathologic Processes Diseases 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
108091000080 Phosphotransferase Proteins 0.000 description 1
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
GMZVRMREEHBGGF-UHFFFAOYSA-N Piracetam Chemical compound NC(=O)CN1CCCC1=O GMZVRMREEHBGGF-UHFFFAOYSA-N 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
102100026286 Protein AF-10 Human genes 0.000 description 1
208000001431 Psychomotor Agitation Diseases 0.000 description 1
VNYBTNPBYXSMOO-UHFFFAOYSA-M Pyridostigmine bromide Chemical compound [Br-].CN(C)C(=O)OC1=CC=C[N+](C)=C1 VNYBTNPBYXSMOO-UHFFFAOYSA-M 0.000 description 1
101100294399 Schizosaccharomyces pombe (strain 972 / ATCC 24843) not1 gene Proteins 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
206010044074 Torticollis Diseases 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
206010044688 Trisomy 21 Diseases 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
150000001242 acetic acid derivatives Chemical class 0.000 description 1
QTBSBXVTEAMEQO-GUEYOVJQSA-N acetic acid-d4 Chemical compound [2H]OC(=O)C([2H])([2H])[2H] QTBSBXVTEAMEQO-GUEYOVJQSA-N 0.000 description 1
RAFKCLFWELPONH-UHFFFAOYSA-N acetonitrile;dichloromethane Chemical compound CC#N.ClCCl RAFKCLFWELPONH-UHFFFAOYSA-N 0.000 description 1
FKCBLVCOSCZFHV-UHFFFAOYSA-N acetonitrile;ethanol Chemical compound CCO.CC#N FKCBLVCOSCZFHV-UHFFFAOYSA-N 0.000 description 1
JUGOREOARAHOCO-UHFFFAOYSA-M acetylcholine chloride Chemical compound [Cl-].CC(=O)OCC[N+](C)(C)C JUGOREOARAHOCO-UHFFFAOYSA-M 0.000 description 1
229960004266 acetylcholine chloride Drugs 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000002535 acidifier Substances 0.000 description 1
230000010933 acylation Effects 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
239000000048 adrenergic agonist Substances 0.000 description 1
239000003513 alkali Substances 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
230000003281 allosteric effect Effects 0.000 description 1
BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
DXUUXWKFVDVHIK-UHFFFAOYSA-N ambenonium chloride Chemical compound [Cl-].[Cl-].C=1C=CC=C(Cl)C=1C[N+](CC)(CC)CCNC(=O)C(=O)NCC[N+](CC)(CC)CC1=CC=CC=C1Cl DXUUXWKFVDVHIK-UHFFFAOYSA-N 0.000 description 1
229960004302 ambenonium chloride Drugs 0.000 description 1
235000019257 ammonium acetate Nutrition 0.000 description 1
229940043376 ammonium acetate Drugs 0.000 description 1
230000003942 amyloidogenic effect Effects 0.000 description 1
206010002022 amyloidosis Diseases 0.000 description 1
238000000540 analysis of variance Methods 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
230000001078 anti-cholinergic effect Effects 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
238000003782 apoptosis assay Methods 0.000 description 1
229960004405 aprotinin Drugs 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 1
238000010533 azeotropic distillation Methods 0.000 description 1
239000003855 balanced salt solution Substances 0.000 description 1
XXRMYXBSBOVVBH-UHFFFAOYSA-N bethanechol chloride Chemical compound [Cl-].C[N+](C)(C)CC(C)OC(N)=O XXRMYXBSBOVVBH-UHFFFAOYSA-N 0.000 description 1
229960002123 bethanechol chloride Drugs 0.000 description 1
230000008238 biochemical pathway Effects 0.000 description 1
238000005842 biochemical reaction Methods 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
GERIGMSHTUAXSI-UHFFFAOYSA-N bis(8-methyl-8-azabicyclo[3.2.1]octan-3-yl) 4-phenyl-2,3-dihydro-1h-naphthalene-1,4-dicarboxylate Chemical group CN1C(C2)CCC1CC2OC(=O)C(C1=CC=CC=C11)CCC1(C(=O)OC1CC2CCC(N2C)C1)C1=CC=CC=C1 GERIGMSHTUAXSI-UHFFFAOYSA-N 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
230000008499 blood brain barrier function Effects 0.000 description 1
210000001218 blood-brain barrier Anatomy 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
238000009835 boiling Methods 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 1
ARUJJNVNLJPSDO-UHFFFAOYSA-N butanamide;hydrochloride Chemical compound Cl.CCCC(N)=O ARUJJNVNLJPSDO-UHFFFAOYSA-N 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
235000011148 calcium chloride Nutrition 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 1
229960004484 carbachol Drugs 0.000 description 1
125000001589 carboacyl group Chemical group 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
230000030833 cell death Effects 0.000 description 1
239000003610 charcoal Substances 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
239000000064 cholinergic agonist Substances 0.000 description 1
239000000812 cholinergic antagonist Substances 0.000 description 1
210000002932 cholinergic neuron Anatomy 0.000 description 1
239000002779 cholinesterase reactivator Substances 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
238000011281 clinical therapy Methods 0.000 description 1
229960002896 clonidine Drugs 0.000 description 1
238000012875 competitive assay Methods 0.000 description 1
230000009850 completed effect Effects 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
230000003750 conditioning effect Effects 0.000 description 1
238000012937 correction Methods 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
229960003280 cupric chloride Drugs 0.000 description 1
238000006210 cyclodehydration reaction Methods 0.000 description 1
238000007405 data analysis Methods 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000006735 deficit Effects 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
YHKBUDZECQDYBR-UHFFFAOYSA-L demecarium bromide Chemical compound [Br-].[Br-].C=1C=CC([N+](C)(C)C)=CC=1OC(=O)N(C)CCCCCCCCCCN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 YHKBUDZECQDYBR-UHFFFAOYSA-L 0.000 description 1
229960003715 demecarium bromide Drugs 0.000 description 1
239000012649 demethylating agent Substances 0.000 description 1
238000000326 densiometry Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
150000004985 diamines Chemical class 0.000 description 1
NTBIYBAYFBNTCD-KBPBESRZSA-N dibenzoyl (2s,3s)-2,3-dihydroxybutanedioate Chemical compound O=C([C@@H](O)[C@H](O)C(=O)OC(=O)C=1C=CC=CC=1)OC(=O)C1=CC=CC=C1 NTBIYBAYFBNTCD-KBPBESRZSA-N 0.000 description 1
WBKFWQBXFREOFH-UHFFFAOYSA-N dichloromethane;ethyl acetate Chemical compound ClCCl.CCOC(C)=O WBKFWQBXFREOFH-UHFFFAOYSA-N 0.000 description 1
SPWVRYZQLGQKGK-UHFFFAOYSA-N dichloromethane;hexane Chemical compound ClCCl.CCCCCC SPWVRYZQLGQKGK-UHFFFAOYSA-N 0.000 description 1
150000005690 diesters Chemical class 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
CZZYITDELCSZES-UHFFFAOYSA-N diphenylmethane Chemical compound C=1C=CC=CC=1CC1=CC=CC=C1 CZZYITDELCSZES-UHFFFAOYSA-N 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
125000004119 disulfanediyl group Chemical group *SS* 0.000 description 1
238000013104 docking experiment Methods 0.000 description 1
229940052764 dopaminergic anti-parkinson drug mao b inhibitors Drugs 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
229940000406 drug candidate Drugs 0.000 description 1
238000001035 drying Methods 0.000 description 1
208000010118 dystonia Diseases 0.000 description 1
BXKDSDJJOVIHMX-UHFFFAOYSA-N edrophonium chloride Chemical compound [Cl-].CC[N+](C)(C)C1=CC=CC(O)=C1 BXKDSDJJOVIHMX-UHFFFAOYSA-N 0.000 description 1
229960002406 edrophonium chloride Drugs 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
238000011067 equilibration Methods 0.000 description 1
LZCLXQDLBQLTDK-BYPYZUCNSA-N ethyl (2S)-lactate Chemical compound CCOC(=O)[C@H](C)O LZCLXQDLBQLTDK-BYPYZUCNSA-N 0.000 description 1
WRCZZMYKSMOYBK-UHFFFAOYSA-N ethyl 2-(1-azabicyclo[2.2.2]octan-3-ylidene)-2-cyanoacetate Chemical compound C1CC2C(=C(C#N)C(=O)OCC)CN1CC2 WRCZZMYKSMOYBK-UHFFFAOYSA-N 0.000 description 1
ZIUSEGSNTOUIPT-UHFFFAOYSA-N ethyl 2-cyanoacetate Chemical compound CCOC(=O)CC#N ZIUSEGSNTOUIPT-UHFFFAOYSA-N 0.000 description 1
WMLCFAVGBHDOIK-UHFFFAOYSA-N ethyl 3-(2-ethoxy-2-oxoethyl)-1-azabicyclo[2.2.2]octane-3-carboxylate Chemical compound C1CC2C(CC(=O)OCC)(C(=O)OCC)CN1CC2 WMLCFAVGBHDOIK-UHFFFAOYSA-N 0.000 description 1
ATZIPACKTBIFAX-UHFFFAOYSA-N ethyl propanimidate;hydrochloride Chemical compound Cl.CCOC(=N)CC ATZIPACKTBIFAX-UHFFFAOYSA-N 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000013213 extrapolation Methods 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
230000003328 fibroblastic effect Effects 0.000 description 1
230000006870 function Effects 0.000 description 1
230000004927 fusion Effects 0.000 description 1
108700039708 galantide Proteins 0.000 description 1
108010074605 gamma-Globulins Proteins 0.000 description 1
239000007789 gas Substances 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
230000003400 hallucinatory effect Effects 0.000 description 1
150000002367 halogens Chemical group 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
230000000971 hippocampal effect Effects 0.000 description 1
102000057063 human MAPT Human genes 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
238000005984 hydrogenation reaction Methods 0.000 description 1
230000003301 hydrolyzing effect Effects 0.000 description 1
DWSGTFTVBLXELC-MOTQWOLNSA-N hydron;[(1r,5s)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 2-hydroxy-2-phenylacetate;bromide Chemical compound Br.C([C@H]1CC[C@@H](C2)N1C)C2OC(=O)C(O)C1=CC=CC=C1 DWSGTFTVBLXELC-MOTQWOLNSA-N 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
208000013403 hyperactivity Diseases 0.000 description 1
150000002462 imidazolines Chemical class 0.000 description 1
238000007654 immersion Methods 0.000 description 1
230000000984 immunochemical effect Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
229910003480 inorganic solid Inorganic materials 0.000 description 1
CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
229960000367 inositol Drugs 0.000 description 1
239000002198 insoluble material Substances 0.000 description 1
239000011872 intimate mixture Substances 0.000 description 1
238000011835 investigation Methods 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
238000002955 isolation Methods 0.000 description 1
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
150000002596 lactones Chemical class 0.000 description 1
CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 1
231100001231 less toxic Toxicity 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000033001 locomotion Effects 0.000 description 1
238000011866 long-term treatment Methods 0.000 description 1
230000007774 longterm Effects 0.000 description 1
235000020121 low-fat milk Nutrition 0.000 description 1
239000012139 lysis buffer Substances 0.000 description 1
230000002132 lysosomal effect Effects 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
238000003760 magnetic stirring Methods 0.000 description 1
230000007257 malfunction Effects 0.000 description 1
238000007726 management method Methods 0.000 description 1
238000000691 measurement method Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
230000006984 memory degeneration Effects 0.000 description 1
208000023060 memory loss Diseases 0.000 description 1
229910052753 mercury Inorganic materials 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229910021645 metal ion Inorganic materials 0.000 description 1
229960002214 methantheline bromide Drugs 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
LZCOQTDXKCNBEE-IKIFYQGPSA-N methscopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)C)=CC=CC=C1 LZCOQTDXKCNBEE-IKIFYQGPSA-N 0.000 description 1
229960001383 methylscopolamine Drugs 0.000 description 1
125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
238000001471 micro-filtration Methods 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004660 morphological change Effects 0.000 description 1
201000003152 motion sickness Diseases 0.000 description 1
230000037023 motor activity Effects 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
230000002911 mydriatic effect Effects 0.000 description 1
CRNIEDSCRWRAHR-UHFFFAOYSA-N n-(4-cyano-1-methylpiperidin-4-yl)acetamide Chemical compound CN1CCC(C#N)(NC(C)=O)CC1 CRNIEDSCRWRAHR-UHFFFAOYSA-N 0.000 description 1
JHGJZJGWJBZWHD-UHFFFAOYSA-N n-[4-(hydroxymethyl)-1-methylpiperidin-4-yl]acetamide Chemical compound CN1CCC(CO)(NC(C)=O)CC1 JHGJZJGWJBZWHD-UHFFFAOYSA-N 0.000 description 1
KWUZCAVKPCRJPO-UHFFFAOYSA-N n-ethyl-4-(6-methyl-1,3-benzothiazol-2-yl)aniline Chemical compound C1=CC(NCC)=CC=C1C1=NC2=CC=C(C)C=C2S1 KWUZCAVKPCRJPO-UHFFFAOYSA-N 0.000 description 1
201000009240 nasopharyngitis Diseases 0.000 description 1
230000008693 nausea Effects 0.000 description 1
LULNWZDBKTWDGK-UHFFFAOYSA-M neostigmine bromide Chemical compound [Br-].CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 LULNWZDBKTWDGK-UHFFFAOYSA-M 0.000 description 1
229960001499 neostigmine bromide Drugs 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
210000003061 neural cell Anatomy 0.000 description 1
210000002241 neurite Anatomy 0.000 description 1
239000003176 neuroleptic agent Substances 0.000 description 1
230000000701 neuroleptic effect Effects 0.000 description 1
230000002232 neuromuscular Effects 0.000 description 1
239000000842 neuromuscular blocking agent Substances 0.000 description 1
230000006576 neuronal survival Effects 0.000 description 1
230000000508 neurotrophic effect Effects 0.000 description 1
239000003367 nicotinic antagonist Substances 0.000 description 1
LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
230000001777 nootropic effect Effects 0.000 description 1
230000001151 other effect Effects 0.000 description 1
OOFGXDQWDNJDIS-UHFFFAOYSA-N oxathiolane Chemical group C1COSC1 OOFGXDQWDNJDIS-UHFFFAOYSA-N 0.000 description 1
150000002918 oxazolines Chemical class 0.000 description 1
238000006213 oxygenation reaction Methods 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
238000011302 passive avoidance test Methods 0.000 description 1
230000009054 pathological process Effects 0.000 description 1
108010091212 pepstatin Proteins 0.000 description 1
FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
208000011906 peptic ulcer disease Diseases 0.000 description 1
238000003359 percent control normalization Methods 0.000 description 1
102000013415 peroxidase activity proteins Human genes 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
235000020030 perry Nutrition 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
102000020233 phosphotransferase Human genes 0.000 description 1
239000006187 pill Substances 0.000 description 1
229960004526 piracetam Drugs 0.000 description 1
RMHMFHUVIITRHF-UHFFFAOYSA-N pirenzepine Chemical compound C1CN(C)CCN1CC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 RMHMFHUVIITRHF-UHFFFAOYSA-N 0.000 description 1
229960004633 pirenzepine Drugs 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004033 plastic Substances 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
230000001242 postsynaptic effect Effects 0.000 description 1
NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
229910000105 potassium hydride Inorganic materials 0.000 description 1
BDAWXSQJJCIFIK-UHFFFAOYSA-N potassium methoxide Chemical compound [K+].[O-]C BDAWXSQJJCIFIK-UHFFFAOYSA-N 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000003518 presynaptic effect Effects 0.000 description 1
230000001686 pro-survival effect Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
230000005522 programmed cell death Effects 0.000 description 1
201000002212 progressive supranuclear palsy Diseases 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
229960005439 propantheline bromide Drugs 0.000 description 1
YORCIIVHUBAYBQ-UHFFFAOYSA-N propargyl bromide Chemical compound BrCC#C YORCIIVHUBAYBQ-UHFFFAOYSA-N 0.000 description 1
LJZPPWWHKPGCHS-UHFFFAOYSA-N propargyl chloride Chemical compound ClCC#C LJZPPWWHKPGCHS-UHFFFAOYSA-N 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
230000006916 protein interaction Effects 0.000 description 1
210000001747 pupil Anatomy 0.000 description 1
KOUKXHPPRFNWPP-UHFFFAOYSA-N pyrazine-2,5-dicarboxylic acid;hydrate Chemical compound O.OC(=O)C1=CN=C(C(O)=O)C=N1 KOUKXHPPRFNWPP-UHFFFAOYSA-N 0.000 description 1
229960002151 pyridostigmine bromide Drugs 0.000 description 1
150000003242 quaternary ammonium salts Chemical class 0.000 description 1
150000008584 quinuclidines Chemical class 0.000 description 1
239000000376 reactant Substances 0.000 description 1
239000000018 receptor agonist Substances 0.000 description 1
229940044601 receptor agonist Drugs 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
230000011514 reflex Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000002787 reinforcement Effects 0.000 description 1
238000009256 replacement therapy Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
206010039083 rhinitis Diseases 0.000 description 1
238000007363 ring formation reaction Methods 0.000 description 1
238000010825 rotarod performance test Methods 0.000 description 1
239000012723 sample buffer Substances 0.000 description 1
230000007017 scission Effects 0.000 description 1
CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
230000009991 second messenger activation Effects 0.000 description 1
230000018448 secretion by cell Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
230000000697 serotonin reuptake Effects 0.000 description 1
239000012679 serum free medium Substances 0.000 description 1
229920002545 silicone oil Polymers 0.000 description 1
210000002027 skeletal muscle Anatomy 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
239000002195 soluble material Substances 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
238000010186 staining Methods 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
235000011149 sulphuric acid Nutrition 0.000 description 1
230000002483 superagonistic effect Effects 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
230000000946 synaptic effect Effects 0.000 description 1
230000009897 systematic effect Effects 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
150000003892 tartrate salts Chemical class 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
231100001274 therapeutic index Toxicity 0.000 description 1
150000003548 thiazolidines Chemical class 0.000 description 1
125000000101 thioether group Chemical group 0.000 description 1
238000004448 titration Methods 0.000 description 1
239000012485 toluene extract Substances 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000583 toxicological profile Toxicity 0.000 description 1
231100000027 toxicology Toxicity 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
238000007492 two-way ANOVA Methods 0.000 description 1
210000003932 urinary bladder Anatomy 0.000 description 1
OYPPVKRFBIWMSX-SXGWCWSVSA-N zimeldine Chemical compound C=1C=CN=CC=1C(=C/CN(C)C)\C1=CC=C(Br)C=C1 OYPPVKRFBIWMSX-SXGWCWSVSA-N 0.000 description 1
229960002791 zimeldine Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D497/10—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/10—Spiro-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Psychiatry (AREA)
Psychology (AREA)
Addiction (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)

NO960225A 1993-07-20 1996-01-18 AZA spiroforbindelser som virker på det cholinergiske system med muscarinisk agonistaktivitet, anvendelse av samme for fremstilling av medikament, farmasöytisk sammensetning omfattende samme samt kjemisk forbindelse til bruk som medikament NO310075B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/094,855 US5534520A (en)	1990-04-10	1993-07-20	Spiro compounds containing five-membered rings
PCT/GB1994/001543 WO1995003303A2 (en)	1993-07-20	1994-07-15	Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity

Publications (3)

Publication Number	Publication Date
NO960225D0 NO960225D0 (no)	1996-01-18
NO960225L NO960225L (no)	1996-03-12
NO310075B1 true NO310075B1 (no)	2001-05-14

Family

ID=22247578

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO960225A NO310075B1 (no)	1993-07-20	1996-01-18	AZA spiroforbindelser som virker på det cholinergiske system med muscarinisk agonistaktivitet, anvendelse av samme for fremstilling av medikament, farmasöytisk sammensetning omfattende samme samt kjemisk forbindelse til bruk som medikament

Country Status (25)

Country	Link
US (1)	US5534520A (pl)
EP (1)	EP0711292B1 (pl)
JP (1)	JP3802050B2 (pl)
KR (1)	KR100341683B1 (pl)
CN (1)	CN1129942B (pl)
AT (1)	ATE212347T1 (pl)
AU (1)	AU696530B2 (pl)
BG (1)	BG62774B1 (pl)
BR (1)	BR9407088A (pl)
CA (1)	CA2167584C (pl)
CZ (1)	CZ295929B6 (pl)
DE (1)	DE69429724T2 (pl)
DK (1)	DK0711292T3 (pl)
ES (1)	ES2171458T3 (pl)
FI (1)	FI113777B (pl)
HU (1)	HU224638B1 (pl)
IL (1)	IL110340A (pl)
NO (1)	NO310075B1 (pl)
NZ (1)	NZ268637A (pl)
PL (1)	PL178931B1 (pl)
PT (1)	PT711292E (pl)
RO (1)	RO117851B1 (pl)
RU (1)	RU2129555C1 (pl)
WO (1)	WO1995003303A2 (pl)
ZA (1)	ZA945284B (pl)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5852029A (en) *	1990-04-10	1998-12-22	Israel Institute For Biological Research	Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity
ES2101291T3 (es) *	1991-11-25	1997-07-01	American Home Prod	1'-amino-2-((benzotiazolil)metil)espiro(isoquinolina-4(1h),3'-pirrolidina)-1,2',3,5'(2h)-tetronas y sus analogos utiles como inhibidores de aldosa reductasa.
PT777671E (pt) *	1994-08-24	2000-08-31	Astrazeneca Ab	Compostos espiro-azabiciclicos uteis em terapia
FR2725206B1 (fr) *	1994-09-29	1996-12-06	Roussel Uclaf	Nouvelles imidazolidines substituees par un heterocycle, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
WO1997011940A1 (en)	1995-09-29	1997-04-03	Eli Lilly And Company	Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation
CA2250417A1 (en)	1996-04-02	1997-10-09	Bayer Aktiengesellschaft	Substituted phenyl keto enols as pesticides and herbicides
EP0932401A1 (en) *	1996-07-01	1999-08-04	Sepracor, Inc.	Methods and compositions for treating urinary incontinence using enantiomerically enriched (r,r)-glycopyrrolate
CN1127333C (zh)	1997-02-24	2003-11-12	S.L.A.药业股份公司	含有胆碱能药物或钙通道阻滞剂的局部用医药组合物
US8048875B1 (en) *	1997-02-24	2011-11-01	S.L.A. Pharma Ag	Topical pharmaceutical composition comprising a cholinergic agent or a calcium channel blocker
NZ500643A (en)	1997-05-30	2001-12-21	Neurosearch As	Spiro-quinuclidine derivatives and their use in treating conditions responsive to nicotinic ACh receptor modulators
TW402591B (en) *	1997-07-11	2000-08-21	Janssen Pharmaceutica Nv	Monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
JP2002517464A (ja) *	1998-06-08	2002-06-18	アドバンスドメディスンインコーポレーテッド	ムスカリン性レセプターアンタゴニスト
PT963985E (pt) *	1998-06-12	2003-06-30	Hoffmann La Roche	Derivados de di- ou triaza-espiro(4,5)decano
ATE222908T1 (de) *	1998-06-12	2002-09-15	Hoffmann La Roche	Spiro(piperidin-4,1'-pyrrolo(3,4-c)pyrrole)
US6353006B1 (en)	1999-01-14	2002-03-05	Bayer Corporation	Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents
US6693202B1 (en)	1999-02-16	2004-02-17	Theravance, Inc.	Muscarinic receptor antagonists
GB9915625D0 (en) *	1999-07-02	1999-09-01	Cortendo Ab	Method
AU2001241056A1 (en) *	2000-03-09	2001-09-17	Mitsubishi Pharma Corporation	Spiro compounds, process for preparing the same and use thereof as drugs
AR035411A1 (es) *	2000-12-29	2004-05-26	Fujisawa Pharmaceutical Co	Uso de un derivado de tacrolimus para fabricar un agente neurotrofico, composiciones y articulos de fabricacion o kits que lo comprenden, metodo para fabricar un agente que lo comprende y tejidos e injertos con una celula nerviosa tratada con este compuesto
DK1385515T3 (da) *	2001-04-18	2008-10-27	Euro Celtique Sa	Spiropyrazole forbindelser
DE10130020A1 (de)	2001-06-25	2003-12-04	Gruenenthal Gmbh	Substituierte 1-Oxa-2,8-diaza-spiro[4.5]dec-2-en-derivate
KR100974901B1 (ko)	2001-12-28	2010-08-10	아카디아 파마슈티칼스 인코포레이티드	모노아민 수용체 조정자로서의 스피로아자사이클릭 화합물
DE10210195B4 (de) *	2002-03-07	2005-12-15	Schwarz Pharma Ag	Verwendung von 1,3-Diazaspiro-[4,5]decan-2,4-dithion zur Behandlung von Schmerz
US7439251B2 (en) *	2002-05-03	2008-10-21	Israel Institute For Biological Research	Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor
RU2238071C2 (ru) *	2002-11-27	2004-10-20	Маркарян Эдуард Георгиевич	Способ лечения пострадавших с черепно-мозговой травмой в ранний посттравматический период
GB0323204D0 (en)	2003-10-03	2003-11-05	Novartis Ag	Organic compounds
US7592348B2 (en)	2003-12-15	2009-09-22	Schering Corporation	Heterocyclic aspartyl protease inhibitors
US7763609B2 (en)	2003-12-15	2010-07-27	Schering Corporation	Heterocyclic aspartyl protease inhibitors
US7700603B2 (en) *	2003-12-15	2010-04-20	Schering Corporation	Heterocyclic aspartyl protease inhibitors
CA2583342A1 (en) *	2004-10-13	2006-04-27	Merck And Co., Inc.	Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzhermer's disease
NZ555624A (en) *	2004-12-09	2009-09-25	Virochem Pharma Inc	Spirotropane compounds and methods for the modulation of CCR5 chemokine receptor activity
EP1824853A4 (en) *	2004-12-09	2010-06-09	Virochem Pharma Inc	NEW SPIROTROPAN COMPOUNDS AND METHOD FOR MODULATING THE ACTIVITY OF THE CHEMOKIN RECEPTOR
US8211904B2 (en) *	2005-07-18	2012-07-03	Merck, Sharp & Dohme Corp.	Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
JP2009506069A (ja)	2005-08-26	2009-02-12	ブレインセルス，インコーポレイティド	ムスカリン性受容体調節による神経発生
EP2258359A3 (en)	2005-08-26	2011-04-06	Braincells, Inc.	Neurogenesis by muscarinic receptor modulation with sabcomelin
ITMI20061279A1 (it) *	2006-06-30	2008-01-01	Consiglio Nazionale Ricerche	Agonisti nicotinici selettivi per il sottotipo recettoriale alfa7,procedimento per la loro preparazione e relative composizioni farmaceutiche
AU2007293416A1 (en) *	2006-09-07	2008-03-13	Merck & Co., Inc.	Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease
EP2068872A1 (en)	2006-09-08	2009-06-17	Braincells, Inc.	Combinations containing a 4-acylaminopyridine derivative
ATE538651T1 (de) *	2006-10-30	2012-01-15	Merck Sharp & Dohme	Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
JP2010512389A (ja)	2006-12-12	2010-04-22	シェーリングコーポレイション	アスパルチルプロテアーゼ阻害剤
KR20090090364A (ko) *	2006-12-12	2009-08-25	쉐링 코포레이션	트리사이클릭 환 시스템을 함유하는 아스파르틸 프로테아제 억제제
US7863291B2 (en) *	2008-04-23	2011-01-04	Bristol-Myers Squibb Company	Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
US9034891B2 (en)	2009-01-26	2015-05-19	Israel Institute For Biological Research	Bicyclic heterocyclic spiro compounds
CA2750777C (en) *	2009-01-26	2018-04-03	Israel Institute For Biological Research	Bicyclic heterocyclic spiro compounds
UA108363C2 (uk)	2009-10-08	2015-04-27		Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
WO2011044184A1 (en)	2009-10-08	2011-04-14	Schering Corporation	Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use
WO2011044185A2 (en)	2009-10-08	2011-04-14	Schering Corporation	Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use
WO2011044187A1 (en)	2009-10-08	2011-04-14	Schering Corporation	Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
AU2009354790A1 (en) *	2009-10-29	2012-06-14	Bristol-Myers Squibb Company	Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
US9145426B2 (en)	2011-04-07	2015-09-29	Merck Sharp & Dohme Corp.	Pyrrolidine-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
WO2012138734A1 (en)	2011-04-07	2012-10-11	Merck Sharp & Dohme Corp.	C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
MX2013011947A (es)	2011-04-13	2014-01-16	Merck Sharp & Dohme	Iminotiazinas 5-sustituidas y sus monoxidos y dioxidos como inhibidores de la enzima que encinde la proteina precursora amiloide en el sitio beta, composiciones y su uso.
KR20140054295A (ko)	2011-08-22	2014-05-08	머크 샤프 앤드 돔 코포레이션	Bace 억제제로서의 2-스피로-치환된 이미노티아진 및 그의 모노- 및 디옥시드, 조성물 및 그의 용도
JP6417324B2 (ja)	2012-07-13	2018-11-07	ペインセラピューティクスインコーポレイテッド	τリン酸化を阻害する方法
WO2014062553A1 (en)	2012-10-17	2014-04-24	Merck Sharp & Dohme Corp.	Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
EP2908825B1 (en)	2012-10-17	2018-04-18	Merck Sharp & Dohme Corp.	Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
CA2894919A1 (en)	2012-12-20	2014-06-26	Merck Sharp & Dohme Corp.	C5,c6 oxacyclic-fused iminothiazine dioxide compounds as bace inhibitors, compositions, and their use
US9489013B2 (en)	2012-12-20	2016-11-08	Merck Sharp & Dohme Corp.	C6-azaspiro iminothiadiazine dioxides as bace inhibitors, compositions, and their use
EP2934534B1 (en)	2012-12-21	2017-12-13	Merck Sharp & Dohme Corp.	C5-spiro iminothiadiazine dioxides as bace inhibitors
EP2968353B1 (en)	2013-03-15	2018-12-19	Merck Sharp & Dohme Corp.	C2-azaspiro iminothiazine dioxides as bace inhibitors
US9433604B2 (en)	2013-10-08	2016-09-06	Pain Therapeutics Inc.	Method for inhibiting growth of cancer cells
EP3083575B1 (en)	2013-12-18	2021-11-03	Merck Sharp & Dohme Corp.	C-6 spirocarbocyclic iminothiadiazine dioxides as bace inhibitors, compositions, and their use
EP3265466A4 (en) *	2015-03-06	2018-12-26	Chase Pharmaceuticals Corporation	Peripheral-anticholinergic muscarinic agonist combination
US10307409B2 (en)	2015-03-06	2019-06-04	Chase Pharmaceuticals Corporation	Muscarinic combinations and their use for combating hypocholinergic disorders of the central nervous system
WO2017044693A1 (en)	2015-09-11	2017-03-16	Chase Pharmaceuticals Corporation	Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system
SI3523310T1 (sl)	2016-10-05	2022-10-28	Nsc Therapeutics Gmbh	Kristalinični polimorfi agonista muskarinskega acetilholinskega receptorja
US12201619B2 (en) *	2018-03-22	2025-01-21	Nsc Therapeutics Gmbh	Compounds and methods for use in the treatment of microglia-mediated disorders
AU2021270664B2 (en) *	2020-05-12	2024-05-30	Beijing Greatway Pharmaceutical Technology Co., Ltd.	Compound for adjusting activity of NMDA receptor, and pharmaceutical composition and use thereof
CA3213079A1 (en)	2021-04-13	2022-10-20	Kristin Lynne ANDREWS	Amino-substituted heterocycles for treating cancers with egfr mutations

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3161644A (en) *	1962-06-22	1964-12-15	Res Lab Dr C Janssen N V	1-benzyl-4-substituted piperidines
JPS4917534B1 (pl) *	1970-10-06	1974-05-01
BE790675A (fr) *	1971-10-29	1973-04-27	Science Union & Cie	Nouveaux derives de l'oxa-1 diaza-3,8 spiro (4,5) decane
EP0189370A3 (de) *	1985-01-16	1988-01-27	Sandoz Ag	Spiro-dioxolane, -dithiolane und -oxothiolane
US4855290A (en) *	1985-05-10	1989-08-08	State Of Israel, Represented By Prime Minister's Office, Israel Institute For Biological Research	Derivatives of quinuclidine
EP0273659A1 (en) *	1986-12-27	1988-07-06	Takeda Chemical Industries, Ltd.	Azaspiro compounds, their production and use
JPS63208590A (ja) *	1987-02-24	1988-08-30	Yamanouchi Pharmaceut Co Ltd	ヘテロ環式スピロ化合物及びその製造法
IL87234A (en) *	1987-08-13	1992-02-16	Israel Inst Biolog Res	Optical isomers of 2-methylspiro(1,3-oxathiolane-5,3')quinuclidine,their preparation and pharmaceutical compositions containing them
ATE122353T1 (de) *	1987-10-05	1995-05-15	Yamanouchi Pharma Co Ltd	Heterozyklische spiroverbindungen und ihre herstellung.
US4876260A (en) *	1987-10-28	1989-10-24	State Of Israel, Israel Institute Of Biological Research	Oxathiolanes
JPH02164882A (ja) *	1988-12-20	1990-06-25	Yamanouchi Pharmaceut Co Ltd	スピロ化合物及びその中間体
JPH02247183A (ja) *	1989-03-20	1990-10-02	Yamanouchi Pharmaceut Co Ltd	ヘテロ環スピロ化合物
YU150489A (sh) *	1989-08-10	1992-12-21	W.L. Gore & Co. Gmbh.	Uređaj za ispitivanje odevnih predmeta na nepromočivost
IL97726A (en) *	1990-04-10	1994-12-29	Israel Inst Biolog Res	Pharmaceutical compositions containing compounds with bridged and unbridged heterocyclic groups, spiro-connected with oxazoline and thiazoline groups, and some new such compounds
US5073560A (en) *	1990-07-20	1991-12-17	Fisons Corporation	Spiro-isoxazolidine derivatives as cholinergic agents
TW201312B (en) *	1991-04-09	1993-03-01	Israel State	Spiro bridged and unbridged heterocyclic compounds

1993
- 1993-07-20 US US08/094,855 patent/US5534520A/en not_active Expired - Lifetime
1994
- 1994-07-15 RU RU96103370A patent/RU2129555C1/ru not_active IP Right Cessation
- 1994-07-15 CZ CZ1996182A patent/CZ295929B6/cs not_active IP Right Cessation
- 1994-07-15 ES ES94921036T patent/ES2171458T3/es not_active Expired - Lifetime
- 1994-07-15 PT PT94921036T patent/PT711292E/pt unknown
- 1994-07-15 BR BR9407088A patent/BR9407088A/pt not_active Application Discontinuation
- 1994-07-15 DK DK94921036T patent/DK0711292T3/da active
- 1994-07-15 RO RO96-00099A patent/RO117851B1/ro unknown
- 1994-07-15 IL IL11034094A patent/IL110340A/xx not_active IP Right Cessation
- 1994-07-15 EP EP94921036A patent/EP0711292B1/en not_active Expired - Lifetime
- 1994-07-15 WO PCT/GB1994/001543 patent/WO1995003303A2/en not_active Ceased
- 1994-07-15 CN CN94192839XA patent/CN1129942B/zh not_active Expired - Fee Related
- 1994-07-15 CA CA002167584A patent/CA2167584C/en not_active Expired - Fee Related
- 1994-07-15 PL PL94312684A patent/PL178931B1/pl not_active IP Right Cessation
- 1994-07-15 JP JP50499595A patent/JP3802050B2/ja not_active Expired - Fee Related
- 1994-07-15 NZ NZ268637A patent/NZ268637A/en not_active IP Right Cessation
- 1994-07-15 AU AU71915/94A patent/AU696530B2/en not_active Ceased
- 1994-07-15 KR KR1019960700296A patent/KR100341683B1/ko not_active Expired - Fee Related
- 1994-07-15 AT AT94921036T patent/ATE212347T1/de not_active IP Right Cessation
- 1994-07-15 DE DE69429724T patent/DE69429724T2/de not_active Expired - Lifetime
- 1994-07-15 HU HU9600126A patent/HU224638B1/hu not_active IP Right Cessation
- 1994-07-19 ZA ZA945284A patent/ZA945284B/xx unknown
1996
- 1996-01-17 FI FI960238A patent/FI113777B/fi active
- 1996-01-18 NO NO960225A patent/NO310075B1/no not_active IP Right Cessation
- 1996-02-19 BG BG100370A patent/BG62774B1/bg unknown

Also Published As

Publication number	Publication date
HU224638B1 (hu)	2005-12-28
HU9600126D0 (en)	1996-03-28
FI960238A7 (fi)	1996-03-18
CN1129942B (zh)	2011-08-10
CN1129942A (zh)	1996-08-28
PT711292E (pt)	2002-07-31
BR9407088A (pt)	1996-08-13
WO1995003303A3 (en)	1995-03-02
PL312684A1 (en)	1996-05-13
AU7191594A (en)	1995-02-20
DE69429724T2 (de)	2002-08-29
IL110340A0 (en)	1994-10-21
AU696530B2 (en)	1998-09-10
JPH09503491A (ja)	1997-04-08
RU2129555C1 (ru)	1999-04-27
JP3802050B2 (ja)	2006-07-26
DE69429724D1 (de)	2002-03-14
BG100370A (bg)	1996-11-29
RO117851B1 (ro)	2002-08-30
ES2171458T3 (es)	2002-09-16
FI113777B (fi)	2004-06-15
CZ18296A3 (en)	1996-07-17
IL110340A (en)	1999-06-20
CA2167584C (en)	2006-10-24
EP0711292B1 (en)	2002-01-23
PL178931B1 (pl)	2000-06-30
NO960225D0 (no)	1996-01-18
CZ295929B6 (cs)	2005-12-14
KR100341683B1 (ko)	2002-11-30
ZA945284B (en)	1995-10-12
HUT74588A (en)	1997-01-28
NO960225L (no)	1996-03-12
US5534520A (en)	1996-07-09
NZ268637A (en)	1998-01-26
DK0711292T3 (da)	2002-05-06
WO1995003303A2 (en)	1995-02-02
KR960703914A (ko)	1996-08-31
EP0711292A1 (en)	1996-05-15
FI960238A0 (fi)	1996-01-17
ATE212347T1 (de)	2002-02-15
BG62774B1 (bg)	2000-07-31
CA2167584A1 (en)	1995-02-02

Legal Events

Date	Code	Title	Description
2012-02-20	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
RU2129555C1 (ru)	1999-04-27	Спиросоединения, содержащие пятичленные кольца, фармацевтический состав
US5852029A (en)	1998-12-22	Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity
KR100247121B1 (ko)	2000-08-01	헤테로시클릭 화합물과 그의 제조방법 및 용도
KR101675174B1 (ko)	2016-11-10	이환형 헤테로사이클릭 스피로 화합물
NO324211B1 (no)	2007-09-10	Nye benzazepinderivater, farmasoytisk middel inneholdende forbindelsene samt deres anvendelse ved fremstilling av medikamenter
NZ536477A (en)	2005-05-27	Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
US20110046160A1 (en)	2011-02-24	Novel Class of Spiro Piperidines for the Treatment of Neurodegenerative Diseases
DE69131409T2 (de)	2000-02-03	Ueberbrückte und nicht-überbrückte heterocyclische Spiroverbindungen
AU2005214319B2 (en)	2009-02-19	Amino heterocyclic modulators of chemokine receptor activity
DE69519315T2 (de)	2001-05-31	Aminoalkyl Benzoxazolinone und Benzothiazolinone, Verfahren zu deren Herstellung und sie enthaltende Zusammensetzungen
US6602865B1 (en)	2003-08-05	Pyridazino(4,5-b)(1,5)oxazepinone, -thiazepinone and -diazepinone compounds
JPH09263585A (ja)	1997-10-07	環状化合物、その製造法および剤
KR20010092424A (ko)	2001-10-24	신규 형태의 축합 피리다지논 화합물
NO304522B1 (no)	1999-01-04	AnologifremgangsmÕte for fremstilling av terapeutisk aktive heterocykliske forbindelser
RS51418B (sr)	2011-02-28	Tetraciklična jedinjenja, postupak za njihovu proizvodnju, farmaceutske smeše koje ih sadrže i njihova upotreba kao liganada dopaminergičnih receptora